SALT LAKE CITY, UTAH - September 17, 2013 (Investorideas.com Mining stocks newswire) Mining stock alert- Inception Mining Inc. (OTCQB: IMII) reported that it has entered into an agreement in principal with Crawford Cattle Company ("Crawford") to acquire over 16,000 net acres of mineral rights in Humboldt and Elko Counties, Nevada, approximately 70 miles north of Winnemucca, Nevada. The acreage lies in or is adjacent to the historic Getchell Trend which is part of the property now under contract to be purchased. Assuming the due diligence and other covenants are satisfied, the acquisition is expected to close no later than the second quarter 2014 of which there is no guarantee.
According to the Company's CEO, Michael Ahlin: "We believe the lands to be acquired are deemed highly prospective given their general location in the Getchell Trend. Specifically, we are under contract to acquire sections of lands that are adjacent to the Turquoise Ridge Property, the Pinson Mine and a lesser amount of acreage near the history Midas Gold Property. The Turquoise Ridge Property is a joint holding of Barrick Gold Corporation (NYSE:ABX) and Newmont Mining Corporation (NYSE:NEM).” At this stage, the Company has not determined or committed to a plan of development and is just now beginning its resource evaluation and long term potential.
The Company is focused on identifying certain historical mining claims that fit strict parameters of proven recoverable grades of minerals, minimal permitting issues, deeded or protected claims, access, acquisition costs that fit our profile and potential refining needs requiring minimal CAPEX or possible toll processing. While the above potential acquisition is a departure from our stated objectives, the opportunity presented must be explored and evaluated as a possible addition to our portfolio of properties.
About Inception Mining Inc . (OTCQB: IMII) We are a mining exploration company engaged in the acquisition, exploration, and development of mineral properties, primarily for high grade gold deposits, from owned mining properties. Our primary target properties are those that have been the subject of historical exploration and have supporting data. Most large visible surface gold mineralized prospects have been explored, mined. What remains are the smaller high-grade mines and prospects previously ignored. www.inceptionmining.com
Turquoise Ridge
The Turquoise Ridge property is located about 70 kilometres northeast of Winnemucca, Nevada, USA. Barrick is the operator and 75% owner of the mine with Newmont owning the remaining 25%.
Turquoise Ridge uses underhand cut-and-fill mining methods due to the relatively low rock quality in the ore zones. Ore is transported to Newmont's Twin Creeks mill for processing. The refractory gold ore is treated by pressure oxidation technology and gold is recovered using conventional carbon-in-leach technology.
In 2009, Turquoise Ridge's production totaled 177koz ounces of gold at total cash costs of $570 per ounce1. Proven and probable mineral reserves as of December 31, 2009 are estimated at 5.47moz of gold.
Source - http://www.infomine.com/minesite/minesite.asp?site=turquoise
Forward-Looking Statements
This news release includes certain forward-looking statements or information. All statements other than statements of historical fact included in this release are forward-looking statements that involve various risks and uncertainties. Forward-looking statements in this news release include statements with respect to the potential mineralization and geological merits of the Company property. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements.
In connection with the forward-looking information contained in this news release, the Company has made numerous assumptions, including that the Company's 2013 exploration programs will proceed as planned and within budget. Inception Mining, Inc. expressly disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise, except as otherwise required by applicable securities legislation.
SOURCE Inception Mining, Inc.
(OTCBB: IMII)
5320 South, 900 E. Suite 260Salt Lake City, Utah 84106
Michael Ahlin CEO
(801) 312-8113 Ext 102
More info on Turquoise Ridge
http://www.infomine.com/minesite/minesite.asp?site=turquoise
Published at Investorideas.com Newswire
Disclaimer/ Disclosure:The Investorideas.com newswire is a third party publisher of news and research as well as creates original content as a news source. Original content created by investorideas is protected by copyright laws other than syndication rights. Investorideas is a news source on Google news and Linkedintoday plus hundreds of syndication partners. Our site does not make recommendations for purchases or sale of stocks or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated by featured companies, news submissions, content marketing and online advertising. Contact each company directly for press release questions. Disclosure is posted on each release if required but otherwise the news was not compensated for and is published for the sole interest of our readers. More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp
Disclosure: Investorideas newswire was paid one thousand dollars to distribute and publish this news release
BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each country.
Tuesday, September 17, 2013
Monday, September 16, 2013
Navada Mining Stock Alert: INCEPTION MINING (OTCQB: IMII) Reports AGREEMENT WITH CRAWFORD CATTLE COMPANY TO ACQUIRE 16,000 NET ACRES OF MINERAL RIGHTS
SALT LAKE CITY, UTAH - September 16, 2013 (Investorideas.com Mining
stocks newswire) Inception Mining Inc. (OTCQB: IMII) announced today
that it has entered into an agreement in principal (the "Agreement")
with Crawford Cattle Company ("Crawford") to acquire over 16,000 net
acres of mineral rights in Humboldt and Elko Counties, Nevada,
approximately 70 miles north of Winnemucca, Nevada. The acreage lies in
or is adjacent to the historic Getchell Trend which is part of the
property now under contract to be purchased. Assuming the due diligence
and other covenants are satisfied, the acquisition is expected to close
no later than the second quarter 2014 of which there is no guarantee.
According to the Company's CEO, Michael Ahlin: “We believe the lands to be acquired are deemed highly prospective given their general location in the Getchell Trend. Specifically, we are under contract to acquire sections of lands that are adjacent to the Turquoise Ridge Property, the Pinson Mine and a lesser amount of acreage near the history Midas Gold Property. The Turquoise Ridge Property is a joint holding of Barrick Gold Corporation (NYSE:ABX) and Newmont Mining Corporation (NYSE:NEM).” At this stage, the Company has not determined or committed to a plan of development and is just now beginning its resource evaluation and long term potential.
The Company is focused on identifying certain historical mining claims that fit strict parameters of proven recoverable grades of minerals, minimal permitting issues, deeded or protected claims, access, acquisition costs that fit our profile and potential refining needs requiring minimal CAPEX or possible toll processing. While the above potential acquisition is a departure from our stated objectives, the opportunity presented must be explored and evaluated as a possible addition to our portfolio of properties.
About Inception Mining Inc. (OTCQB: IMII) We are a mining exploration company engaged in the acquisition, exploration, and development of mineral properties, primarily for high grade gold deposits, from owned mining properties. Our primary target properties are those that have been the subject of historical exploration and have supporting data. Most large visible surface gold mineralized prospects have been explored, mined. What remains are the smaller high-grade mines and prospects previously ignored. www.inceptionmining.com
Forward-Looking Statements
This news release includes certain forward-looking statements or information. All statements other than statements of historical fact included in this release are forward-looking statements that involve various risks and uncertainties. Forward-looking statements in this news release include statements with respect to the potential mineralization and geological merits of the Company property. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements.
In connection with the forward-looking information contained in this news release, the Company has made numerous assumptions, including that the Company’s 2013 exploration programs will proceed as planned and within budget. Inception Mining, Inc. expressly disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise, except as otherwise required by applicable securities legislation.
SOURCE Inception Mining, Inc.
(OTCBB: IMII)
5320 South, 900 E. Suite 260
Salt Lake City, Utah 84106
Michael Ahlin CEO
(801) 312-8113 Ext 102
More info on Turquoise Ridge
http://www.infomine.com/minesite/minesite.asp?site=turquoise
Published at Investorideas.com Newswire
Disclaimer/ Disclosure:The Investorideas.com newswire is a third party publisher of news and research as well as creates original content as a news source. Original content created by investorideas is protected by copyright laws other than syndication rights. Investorideas is a news source on Google news and Linkedintoday plus hundreds of syndication partners. Our site does not make recommendations for purchases or sale of stocks or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated by featured companies, news submissions, content marketing and online advertising. Contact each company directly for press release questions. Disclosure is posted on each release if required but otherwise the news was not compensated for and is published for the sole interest of our readers. More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp
Disclosure: Investorideas newswire was paid one thousand dollars to distribute and publish this news release
BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each country.
According to the Company's CEO, Michael Ahlin: “We believe the lands to be acquired are deemed highly prospective given their general location in the Getchell Trend. Specifically, we are under contract to acquire sections of lands that are adjacent to the Turquoise Ridge Property, the Pinson Mine and a lesser amount of acreage near the history Midas Gold Property. The Turquoise Ridge Property is a joint holding of Barrick Gold Corporation (NYSE:ABX) and Newmont Mining Corporation (NYSE:NEM).” At this stage, the Company has not determined or committed to a plan of development and is just now beginning its resource evaluation and long term potential.
The Company is focused on identifying certain historical mining claims that fit strict parameters of proven recoverable grades of minerals, minimal permitting issues, deeded or protected claims, access, acquisition costs that fit our profile and potential refining needs requiring minimal CAPEX or possible toll processing. While the above potential acquisition is a departure from our stated objectives, the opportunity presented must be explored and evaluated as a possible addition to our portfolio of properties.
About Inception Mining Inc. (OTCQB: IMII) We are a mining exploration company engaged in the acquisition, exploration, and development of mineral properties, primarily for high grade gold deposits, from owned mining properties. Our primary target properties are those that have been the subject of historical exploration and have supporting data. Most large visible surface gold mineralized prospects have been explored, mined. What remains are the smaller high-grade mines and prospects previously ignored. www.inceptionmining.com
Forward-Looking Statements
This news release includes certain forward-looking statements or information. All statements other than statements of historical fact included in this release are forward-looking statements that involve various risks and uncertainties. Forward-looking statements in this news release include statements with respect to the potential mineralization and geological merits of the Company property. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements.
In connection with the forward-looking information contained in this news release, the Company has made numerous assumptions, including that the Company’s 2013 exploration programs will proceed as planned and within budget. Inception Mining, Inc. expressly disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise, except as otherwise required by applicable securities legislation.
SOURCE Inception Mining, Inc.
(OTCBB: IMII)
5320 South, 900 E. Suite 260
Salt Lake City, Utah 84106
Michael Ahlin CEO
(801) 312-8113 Ext 102
More info on Turquoise Ridge
http://www.infomine.com/minesite/minesite.asp?site=turquoise
Published at Investorideas.com Newswire
Disclaimer/ Disclosure:The Investorideas.com newswire is a third party publisher of news and research as well as creates original content as a news source. Original content created by investorideas is protected by copyright laws other than syndication rights. Investorideas is a news source on Google news and Linkedintoday plus hundreds of syndication partners. Our site does not make recommendations for purchases or sale of stocks or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated by featured companies, news submissions, content marketing and online advertising. Contact each company directly for press release questions. Disclosure is posted on each release if required but otherwise the news was not compensated for and is published for the sole interest of our readers. More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp
Disclosure: Investorideas newswire was paid one thousand dollars to distribute and publish this news release
BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each country.
Solar Stock XsunX, Inc. (OTCQB: XSNX) Update: 750 kW in Proposals Going Out - More Projects in Review
New York, NY, Point Roberts, WA - September 16, 2013
(Investorideas.com renewable energy newswire) Investorideas.com, an
investor research portal specializing in investing ideas in leading
sectors including renewable energy stocks, issues a corporate and
industry update for solar stock, XsunX, Inc. (OTCQB: XSNX), entitled 750 kW in Proposals Going Out - More Projects in Review.
Tom M. Djokovich, CEO of XsunX, Inc. (OTCQB: XSNX) said in the corporate/ industry update:”
At the start of the month, we outlined how September's marketing and sales efforts would focus on supporting and meeting with prospective customers for our CIGS manufacturing technology, and that we would be responding to solar power system development quote requests for commercial and utility scale projects.”
Continued...
So far, September has been busy in a very good way. Progress filling our solar power system development sales pipeline is picking up steam very nicely with three projects totaling nearly 750 kW (about ¾ of a megawatt) for commercial and industrial projects now in the proposal stage - exciting stuff.
There are more projects pending that we have been asked to bid on as they become ready for the engineering, systems procurement, and the construction phase. Additionally, in an effort to try to develop as much sales opportunity as possible, we are not just waiting on projects to come our way, but have also begun reaching out to land owners we know to offer free solar development feasibility assessments of properties they hold.
On the CIGS manufacturing equipment side of operations, we have an on-site meeting with an African based client scheduled for this week, and last Thursday we delivered to a Caribbean based client an extensive package of specifications and financial benefit outlines they requested to allow them to better qualify for government support in their region.
Overall, our expansion into solar project construction and development has started with strong momentum and we are excited about the opportunity to grow sales and operations through these new efforts. With USA solar installation up over 30% in the first quarter and increasing another 15% in the second quarter, our focus is to use the increase in awareness of solar's affordability to load the sales pipeline with commercial, industrial, and utility scale projects.
Source: http://www.xsunx.com/news.php?nid=371
More About XsunX (OTCQB: XSNX)
XsunX, Inc. is working to commercialize a new manufacturing process to produce low cost, high efficiency thin-film Copper Indium Gallium (di) Selenide (CIGS) thin film solar cells. Our patent-pending processing technology, which we call CIGSolar®, focuses on the mass production of thin-film CIGS solar cells utilizing a proprietary multi-area thermal deposition process to minimize processing defects to create highly uniform CIGS films. These cells match silicon solar cell dimensions and can be offered as a non-toxic, high-efficiency and lowest-cost alternative to the use of silicon solar cells. The company is offering licenses for the use of the CIGSolar® process technology, and plans to generate revenue through licensing fees and manufacturing royalties for the use of the CIGSolar® technology.
For more information please call XsunX at 888-797-4527, or visit the company's website at www.xsunx.com
About InvestorIdeas.com:
InvestorIdeas.com is a leader in investor stock research by sector, featuring stock news, commentary and trading alerts in leading sectors including biotech, tech, mining, energy, water, renewable energy, beverage stocks and more.
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Follow Investorideas.com News on Linkedin.com/today at http://www.linkedin.com/today/investorideas.com
Sign up for solar and renewable energy stock news alerts
http://www.investorideas.com/Resources/Newsletter.asp
Become an Investorideas.com Member and access our 14 online stock directories 24/7 - water, renewable energy, mining stocks and more...
http://www.investorideas.com/membership/
Disclaimer/ Disclosure : The Investorideas.com newswire is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. Disclosure: Investorideas has been compensated by XSNX for news distribution averaging 1500 per month
http://www.investorideas.com/About/Disclaimer.asp
This site is currently compensated by featured companies, news submissions and online advertising.
BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar Global investors must adhere to regulations of each country.
800-665-0411 - Source - www.Investorideas.com
At the start of the month, we outlined how September's marketing and sales efforts would focus on supporting and meeting with prospective customers for our CIGS manufacturing technology, and that we would be responding to solar power system development quote requests for commercial and utility scale projects.”
Continued...
So far, September has been busy in a very good way. Progress filling our solar power system development sales pipeline is picking up steam very nicely with three projects totaling nearly 750 kW (about ¾ of a megawatt) for commercial and industrial projects now in the proposal stage - exciting stuff.
There are more projects pending that we have been asked to bid on as they become ready for the engineering, systems procurement, and the construction phase. Additionally, in an effort to try to develop as much sales opportunity as possible, we are not just waiting on projects to come our way, but have also begun reaching out to land owners we know to offer free solar development feasibility assessments of properties they hold.
On the CIGS manufacturing equipment side of operations, we have an on-site meeting with an African based client scheduled for this week, and last Thursday we delivered to a Caribbean based client an extensive package of specifications and financial benefit outlines they requested to allow them to better qualify for government support in their region.
Overall, our expansion into solar project construction and development has started with strong momentum and we are excited about the opportunity to grow sales and operations through these new efforts. With USA solar installation up over 30% in the first quarter and increasing another 15% in the second quarter, our focus is to use the increase in awareness of solar's affordability to load the sales pipeline with commercial, industrial, and utility scale projects.
Source: http://www.xsunx.com/news.php?nid=371
More About XsunX (OTCQB: XSNX)
XsunX, Inc. is working to commercialize a new manufacturing process to produce low cost, high efficiency thin-film Copper Indium Gallium (di) Selenide (CIGS) thin film solar cells. Our patent-pending processing technology, which we call CIGSolar®, focuses on the mass production of thin-film CIGS solar cells utilizing a proprietary multi-area thermal deposition process to minimize processing defects to create highly uniform CIGS films. These cells match silicon solar cell dimensions and can be offered as a non-toxic, high-efficiency and lowest-cost alternative to the use of silicon solar cells. The company is offering licenses for the use of the CIGSolar® process technology, and plans to generate revenue through licensing fees and manufacturing royalties for the use of the CIGSolar® technology.
For more information please call XsunX at 888-797-4527, or visit the company's website at www.xsunx.com
About InvestorIdeas.com:
InvestorIdeas.com is a leader in investor stock research by sector, featuring stock news, commentary and trading alerts in leading sectors including biotech, tech, mining, energy, water, renewable energy, beverage stocks and more.
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Follow Investorideas.com News on Linkedin.com/today at http://www.linkedin.com/today/investorideas.com
Sign up for solar and renewable energy stock news alerts
http://www.investorideas.com/Resources/Newsletter.asp
Become an Investorideas.com Member and access our 14 online stock directories 24/7 - water, renewable energy, mining stocks and more...
http://www.investorideas.com/membership/
Disclaimer/ Disclosure : The Investorideas.com newswire is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. Disclosure: Investorideas has been compensated by XSNX for news distribution averaging 1500 per month
http://www.investorideas.com/About/Disclaimer.asp
This site is currently compensated by featured companies, news submissions and online advertising.
BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar Global investors must adhere to regulations of each country.
800-665-0411 - Source - www.Investorideas.com
Mobile Security and Biometrics Sector Snapshot: AAPL, NXTD
New York, NY - September 16, 2013 (www.investorideas.com newswire)
Investorideas.com, an investor research portal specializing in investor
research in leading sectors, issues commentary on the mobile security
sector . Frost & Sullivan’s Global Program Director, ICT in
Financial Services, Jean-Noel Georges and Alan Goode, Managing Director
from Goode Intelligence share insight into the rapidly changing sector
and comment on Apple’s (AAPL) recent implementation of fingerprint biometrics.
Additionally the CEO of an industry newcomer NXT-ID, Inc. ( OTCQB: NXTD), shares his perspective on the future of biometrics for identification and verification.
Last year Goode Intelligence predicted that mobile biometric security would move from "an interesting concept” to a "must-have” feature for all smart mobile devices (SMDs) His predictions have come to fruition.
Alan Goode, Managing Director of GoodeIntelligence.com recently shared his insight with Investorideas.com telling us, "I believe that the main driver for adoption of biometrics into consumer electronic devices is the mass adoption of smart mobile devices and the challenges this poses for strong authentication and identity verification - in other words how do we securely prove identity on a mobile device without affecting the user experience. Passcodes and One-Time-Passwords are not the most convenient way to prove identity on a mobile device, especially when we are on the move. As more and more of our daily lives are being managed by these devices, having to authenticate using technology that was designed for a personal computer
and a keyboard is becoming undesirable. "
"What Apple ( AAPL ) has done with Touch ID is to improve the usability of identity verification on mobile devices - to make it more convenient. "
He also sees biometrics playing a key role in other technology, saying "There is a move to make authentication and identity verification on mobile devices more convenient and biometrics can provide a solution to this. This includes many biometric modalities including fingerprint, voice, facial and eye verification technologies. We predict that we shall see a marked increase in consumer technology supporting biometric authentication. Not just mobile phones, but smart TVs, games consoles, cars and wearable technology. Take a look at the latest Xbox console, Xbox one - it supports voice and facial recognition. Multi-factor biometric authentication can support many endpoints and ensure that we have a continuous experience when we switch between endpoints (NOTE: Take a look at this video from Nuance for a glimpse into what can happen with cross-platform voice recognition.” (http://venturebeat.com/2013/09/08/how-nuance-tapped-the-cloud-to-bring-voice-recognition-to-mobile/).
Mr. Gino M. Pereira, Chief Executive Officer of NXT-ID, Inc. ( OTCQB: NXTD said "Over the past couple of years it has become apparent that simple password protection is not sufficient in today's increasingly sophisticated hacking world. Now giants such as Apple ( AAPL ) and Google ( GOOG) are publically saying so. The next few years will see increasing usage of all different forms of biometrics for identification and verification. One day somewhere in the future we will seamlessly have access to our homes, cars, computers
and other devices simply by being in proximity to them and being
recognized biometrically. It will be simple, seemless and more secure "
NXT-ID is launching an advanced MobileBio™ technology that secures consumers' platforms via innovative authentication and encryption.
The first product the company is launching later this year is the Wocket™, a unique technology with a very different approach to payment security. Instead of replacing the wallet, they are aiming to improve upon it. The Wocket™ reduces the number of cards in your wallet while supports virtually every payment method currently available at Point-of-Sale (POS) at retailers around the world including magnetic stripe, EMV/NFC and barcode…all within a secure vault within a wallet.
Analyst Jean-Noel George from Frost & Sullivan recently said, "Protecting the mobile device itself is a first step, necessary to secure mobile payments. Although a personal identification number (PIN) can do the job, in 2011 more than 60 percent of smartphone users were not using a PIN to protect their mobile access. "
"The time is now right for biometric technology to emerge as a secure solution for mobile applications that require high levels of security, particularly payment," said Mr. Georges. "From a pure-payment security point of view, biometrics has already delivered significant advantages."
Investorideas.com asked him how long he thinks it will take for NFC or touchless payments to be in widespread use for payments in the US and what percentage of credit card holders in the US currently use NFC to make payments and how does he see that number changing over the next 5 years ?
He noted. " For the payment industry, the US market moved directly from magnetic stripe payment card to contactless payment cards. The infrastructure (POS, ATM) are being changed to accept contactless payment cards in the US. Major industry players (financial institutions, MNOs, OEM handset vendors,...) are deeply involved in the NFC technology. We can also add ISIS as a perfect driver for a US massive roll out. But the reality is different, and having NFC capabilities on your smartphone, does not automatically generate end user massive adoption and usages. I do not see NFC in the US as an important means of payment before 2015. "
"If you are back to the means of payment industry, it took 2 decades in Europe to move from cash/coins to EMV card payment. In the US, it will take time for the end user to move from the well known bank card to a NFC mobile payment. "
In discussing how the wallet war shifting to an MPOS war he said, " Many players already entered to the wallet war (software vendors, banks, financial institutions, ...) without a real leader. I can see the same business orientation coming to the mPOS. Many players are entering to this market with a plethora of solutions, but at the moment none took the lead. For SMB and SME, there is a real value added to use mPOS instead of traditional POS hardware. They just need to add a small add-on (most of the time for free) and they will be charged a little more than traditional fees but only based on their sales. Some business models have fixed fees based on your sales amount. So you have to pay even when you did not sale anything, which I s not comfortable for the retailer. The platform to be used is your own device (smartphone and/or tablet).
Commenting on Apple's ( AAPL ) recent acquisition of Authen Tec fingerprint biometric technology Jean-Noel said, " As I said, fingerprint recognition made lot of progress in terms of quality, speed and of price (as finger print readers were not doing perfect recognition. New ones are doing several pictures of your finger to obtain a better result). Apple just confirmed the rumors were referring to. The quality level of fingerprint technology reached a sufficient level at that time. So I don't think that a multimodal solution for basic application will be a major trend in a short time. I heard about Validity Sensors Inc doing the same."
In terms of industry growth he told us . " We are forecasting for Europe a €151 billion in 2017, and €502 billion in 2017 globally. Once again, mobile payment included for us, SMS, USSD, online payment, NFC, P2P and cloud based payment. I can see that Identity Access Management (IAM) is one of the biggest growth opportunities for the security mobile industry. We are forecasting 1.14 billions smartphone devices in 2017 with associated revenue of $371 billion. "
Noting key trends for investors following the mobile payment and mobile security space he commented, " IAM will be key for mobile security. I saw that to overpass the lack of adoption and the complex ecosystem, many players are using cloud based credential for payment. Cloud solutions for payment are definitively a trend to follow. You have cost efficiency, easy to use and a sufficient security level. Cloud will be strategic in the future. Apple already mentioned that biometric data will not be stored on the cloud....but for how long?"
About Frost & Sullivan
Frost & Sullivan, the Growth Partnership Company, enables clients to accelerate growth and achieve best in class positions in growth, innovation and leadership. The company's Growth Partnership Service provides the CEO and the CEO's Growth Team with disciplined research and best practice models to drive the generation, evaluation and implementation of powerful growth strategies. Frost & Sullivan leverages over 50 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from more than 40 offices on six continents. To join our Growth Partnership, please visit http://www.frost.com.
About InvestorIdeas.com: Big Ideas for global investors
InvestorIdeas.com is a leader in investor stock research by sector, featuring stock news, commentary and trading alerts in leading sectors including biotech, tech, mining, energy, water, renewable energy, beverage stocks and more.
Research Biometrics Stocks at Investorideas.com stock directory
http://www.investorideas.com/BPS/Stock_List.asp
Sign up for free stock alerts
http://www.investorideas.com/Resources/Newsletter.asp
Published at the Investorideas.com Newswire - Big ideas for Global Investors
Disclaimer/ Disclosure: The Investorideas.com newswire is a third party publisher of news and research as well as creates original content as a news source. Original content created by investorideas is protected by copyright laws other than syndication rights. Investorideas is a news source on Google news and Linkedintoday plus hundreds of syndication partners. Our site does not make recommendations for purchases or sale of stocks or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated by featured companies, news submissions, content marketing and online advertising. Contact each company directly for press release questions. Disclosure is posted on each release if required but otherwise the news was not compensated for and is published for the sole interest of our readers. Disclosure: Investorideas has been compensated by NXTD: five thousand per month plus 144 shares.
More info : http://www.investorideas.com/About/Disclaimer.asp
BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each country.
800-665-0411 or 212-822-8842 Source - www.Investorideas.com
Last year Goode Intelligence predicted that mobile biometric security would move from "an interesting concept” to a "must-have” feature for all smart mobile devices (SMDs) His predictions have come to fruition.
Alan Goode, Managing Director of GoodeIntelligence.com recently shared his insight with Investorideas.com telling us, "I believe that the main driver for adoption of biometrics into consumer electronic devices is the mass adoption of smart mobile devices and the challenges this poses for strong authentication and identity verification - in other words how do we securely prove identity on a mobile device without affecting the user experience. Passcodes and One-Time-Passwords are not the most convenient way to prove identity on a mobile device, especially when we are on the move. As more and more of our daily lives are being managed by these devices, having to authenticate using technology that was designed for a personal computer
and a keyboard is becoming undesirable. ""What Apple ( AAPL ) has done with Touch ID is to improve the usability of identity verification on mobile devices - to make it more convenient. "
He also sees biometrics playing a key role in other technology, saying "There is a move to make authentication and identity verification on mobile devices more convenient and biometrics can provide a solution to this. This includes many biometric modalities including fingerprint, voice, facial and eye verification technologies. We predict that we shall see a marked increase in consumer technology supporting biometric authentication. Not just mobile phones, but smart TVs, games consoles, cars and wearable technology. Take a look at the latest Xbox console, Xbox one - it supports voice and facial recognition. Multi-factor biometric authentication can support many endpoints and ensure that we have a continuous experience when we switch between endpoints (NOTE: Take a look at this video from Nuance for a glimpse into what can happen with cross-platform voice recognition.” (http://venturebeat.com/2013/09/08/how-nuance-tapped-the-cloud-to-bring-voice-recognition-to-mobile/).
Mr. Gino M. Pereira, Chief Executive Officer of NXT-ID, Inc. ( OTCQB: NXTD said "Over the past couple of years it has become apparent that simple password protection is not sufficient in today's increasingly sophisticated hacking world. Now giants such as Apple ( AAPL ) and Google ( GOOG) are publically saying so. The next few years will see increasing usage of all different forms of biometrics for identification and verification. One day somewhere in the future we will seamlessly have access to our homes, cars, computers
and other devices simply by being in proximity to them and being
recognized biometrically. It will be simple, seemless and more secure "NXT-ID is launching an advanced MobileBio™ technology that secures consumers' platforms via innovative authentication and encryption.
The first product the company is launching later this year is the Wocket™, a unique technology with a very different approach to payment security. Instead of replacing the wallet, they are aiming to improve upon it. The Wocket™ reduces the number of cards in your wallet while supports virtually every payment method currently available at Point-of-Sale (POS) at retailers around the world including magnetic stripe, EMV/NFC and barcode…all within a secure vault within a wallet.
Analyst Jean-Noel George from Frost & Sullivan recently said, "Protecting the mobile device itself is a first step, necessary to secure mobile payments. Although a personal identification number (PIN) can do the job, in 2011 more than 60 percent of smartphone users were not using a PIN to protect their mobile access. "
"The time is now right for biometric technology to emerge as a secure solution for mobile applications that require high levels of security, particularly payment," said Mr. Georges. "From a pure-payment security point of view, biometrics has already delivered significant advantages."
Investorideas.com asked him how long he thinks it will take for NFC or touchless payments to be in widespread use for payments in the US and what percentage of credit card holders in the US currently use NFC to make payments and how does he see that number changing over the next 5 years ?
He noted. " For the payment industry, the US market moved directly from magnetic stripe payment card to contactless payment cards. The infrastructure (POS, ATM) are being changed to accept contactless payment cards in the US. Major industry players (financial institutions, MNOs, OEM handset vendors,...) are deeply involved in the NFC technology. We can also add ISIS as a perfect driver for a US massive roll out. But the reality is different, and having NFC capabilities on your smartphone, does not automatically generate end user massive adoption and usages. I do not see NFC in the US as an important means of payment before 2015. "
"If you are back to the means of payment industry, it took 2 decades in Europe to move from cash/coins to EMV card payment. In the US, it will take time for the end user to move from the well known bank card to a NFC mobile payment. "
In discussing how the wallet war shifting to an MPOS war he said, " Many players already entered to the wallet war (software vendors, banks, financial institutions, ...) without a real leader. I can see the same business orientation coming to the mPOS. Many players are entering to this market with a plethora of solutions, but at the moment none took the lead. For SMB and SME, there is a real value added to use mPOS instead of traditional POS hardware. They just need to add a small add-on (most of the time for free) and they will be charged a little more than traditional fees but only based on their sales. Some business models have fixed fees based on your sales amount. So you have to pay even when you did not sale anything, which I s not comfortable for the retailer. The platform to be used is your own device (smartphone and/or tablet).
Commenting on Apple's ( AAPL ) recent acquisition of Authen Tec fingerprint biometric technology Jean-Noel said, " As I said, fingerprint recognition made lot of progress in terms of quality, speed and of price (as finger print readers were not doing perfect recognition. New ones are doing several pictures of your finger to obtain a better result). Apple just confirmed the rumors were referring to. The quality level of fingerprint technology reached a sufficient level at that time. So I don't think that a multimodal solution for basic application will be a major trend in a short time. I heard about Validity Sensors Inc doing the same."
In terms of industry growth he told us . " We are forecasting for Europe a €151 billion in 2017, and €502 billion in 2017 globally. Once again, mobile payment included for us, SMS, USSD, online payment, NFC, P2P and cloud based payment. I can see that Identity Access Management (IAM) is one of the biggest growth opportunities for the security mobile industry. We are forecasting 1.14 billions smartphone devices in 2017 with associated revenue of $371 billion. "
Noting key trends for investors following the mobile payment and mobile security space he commented, " IAM will be key for mobile security. I saw that to overpass the lack of adoption and the complex ecosystem, many players are using cloud based credential for payment. Cloud solutions for payment are definitively a trend to follow. You have cost efficiency, easy to use and a sufficient security level. Cloud will be strategic in the future. Apple already mentioned that biometric data
will not be stored on the cloud....but for how long?"About Frost & Sullivan
Frost & Sullivan, the Growth Partnership Company, enables clients to accelerate growth and achieve best in class positions in growth, innovation and leadership. The company's Growth Partnership Service provides the CEO and the CEO's Growth Team with disciplined research and best practice models to drive the generation, evaluation and implementation of powerful growth strategies. Frost & Sullivan leverages over 50 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from more than 40 offices on six continents. To join our Growth Partnership, please visit http://www.frost.com.
About InvestorIdeas.com: Big Ideas for global investors
InvestorIdeas.com is a leader in investor stock research by sector, featuring stock news, commentary and trading alerts in leading sectors including biotech, tech, mining, energy, water, renewable energy, beverage stocks and more.
Research Biometrics Stocks at Investorideas.com stock directory
http://www.investorideas.com/BPS/Stock_List.asp
Sign up for free stock alerts
http://www.investorideas.com/Resources/Newsletter.asp
Published at the Investorideas.com Newswire - Big ideas for Global Investors
Disclaimer/ Disclosure: The Investorideas.com newswire is a third party publisher of news and research as well as creates original content as a news source. Original content created by investorideas is protected by copyright laws other than syndication rights. Investorideas is a news source on Google news and Linkedintoday plus hundreds of syndication partners. Our site does not make recommendations for purchases or sale of stocks or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated by featured companies, news submissions, content marketing and online advertising. Contact each company directly for press release questions. Disclosure is posted on each release if required but otherwise the news was not compensated for and is published for the sole interest of our readers. Disclosure: Investorideas has been compensated by NXTD: five thousand per month plus 144 shares.
More info : http://www.investorideas.com/About/Disclaimer.asp
BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each country.
800-665-0411 or 212-822-8842 Source - www.Investorideas.com
Friday, September 13, 2013
Medical Technology Stock Trading Alert: Aethlon Medical (OTCQB: AEMD) Closes up 12% on News of Launch of Exosome Science Subsidiary
Point Roberts, WA, New York, NY - September 13, 2013
(Investorideas.com newswire) Investorideas.com, an investor research
portal specializing in investing ideas in leading sectors including
biotech and medical technology stocks, issues a technical trading alert
for Aethlon Medical, Inc. (OTCQB: AEMD).
The stock closed trading on Thursday at $0.18, up $0.02 or 12.43% on
volume of over 400,000 shares following news of a new Exosome Science
subsidiary.
The company on Thursday announced the formal launch of Exosome
Sciences, Inc. (ESI), a wholly-owned subsidiary previously established
by Aethlon to pursue exosome-based strategies to diagnose and monitor
the progression of cancer, infectious disease and other life-threatening
conditions. Exosomes produced by diseased cells represent an optimal
diagnostic target as they are shed into bodily fluids such as urine and
blood where they can be easily accessed. Exosomes transport specific
disease-origin markers that provide the basis for ESI to establish
non-invasive liquid biopsies to diagnose and monitor a wide-range of
disease conditions.
About Aethlon Medical (OTCQB: AEMD)
Aethlon Medical creates innovative medical devices that address unmet medical needs in cancer, infectious disease, and other life-threatening conditions. Our Aethlon ADAPT™ System is a revenue-stage technology platform that provides the basis for a new class of devices the rapid, yet selective removal of disease promoting particles from the entire circulatory system. At present, The Aethlon ADAPT product pipeline includes the Aethlon Hemopurifier to address infectious disease and cancer, and a medical device being developed under a 5-year contract with DARPA to reduce the incidence of sepsis in combat-injured soldiers. For more information, please visit www.aethlonmedical.com.
About InvestorIdeas.com: Big Ideas for global investors
InvestorIdeas.com is a leader in investor stock research by sector, featuring stock news, commentary and trading alerts in leading sectors including biotech, tech, mining, energy, water, renewable energy, beverage stocks and more.
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Follow Investorideas.com News on Linkedin.com/today at http://www.linkedin.com/today/investorideas.com
Sign up for free stock alerts
http://www.investorideas.com/Resources/Newsletter.asp
Research more biotech and medical technology stocks:
http://www.investorideas.com/membership/
Disclaimer/ Disclosure: The Investorideas.com newswire is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising. Disclosure: Investorideas has been compensated by AEMD for news release distribution and content publishing: three thousand per month effective June 2013 http://www.investorideas.com/About/Disclaimer.asp BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar
800-665-0411 - or 212-822-8842Source - www.Investorideas.com
About Aethlon Medical (OTCQB: AEMD) Aethlon Medical creates innovative medical devices that address unmet medical needs in cancer, infectious disease, and other life-threatening conditions. Our Aethlon ADAPT™ System is a revenue-stage technology platform that provides the basis for a new class of devices the rapid, yet selective removal of disease promoting particles from the entire circulatory system. At present, The Aethlon ADAPT product pipeline includes the Aethlon Hemopurifier to address infectious disease and cancer, and a medical device being developed under a 5-year contract with DARPA to reduce the incidence of sepsis in combat-injured soldiers. For more information, please visit www.aethlonmedical.com.
About InvestorIdeas.com: Big Ideas for global investors
InvestorIdeas.com is a leader in investor stock research by sector, featuring stock news, commentary and trading alerts in leading sectors including biotech, tech, mining, energy, water, renewable energy, beverage stocks and more.
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Follow Investorideas.com News on Linkedin.com/today at http://www.linkedin.com/today/investorideas.com
Sign up for free stock alerts
http://www.investorideas.com/Resources/Newsletter.asp
Research more biotech and medical technology stocks:
http://www.investorideas.com/membership/
Disclaimer/ Disclosure: The Investorideas.com newswire is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising. Disclosure: Investorideas has been compensated by AEMD for news release distribution and content publishing: three thousand per month effective June 2013 http://www.investorideas.com/About/Disclaimer.asp BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar
800-665-0411 - or 212-822-8842Source - www.Investorideas.com
Medical Technology Breaking News: Aethlon Medical (OTCQB: AEMD) Announces Dr. Douglas Taylor as Chief Scientific Officer of Exosome Sciences, Inc.
SAN DIEGO - September 13, 2013 (Investorideas.com newswire) Aethlon Medical, Inc. (OTCBB:AEMD),
announced today that Dr. Douglas Taylor has accepted the position of
Chief Scientific Officer at Exosome Sciences, Inc. (ESI), a wholly owned
diagnostic subsidiary of Aethlon Medical. Dr. Taylor is credited with
the discovery of tumor-secreted exosomes and is a leading published
author on the topic. "We are truly honored that Dr. Taylor has agreed to
lead our research endeavors at Exosome Sciences. His pioneering
research has been instrumental in establishing an industry for
exosome-based diagnostics and therapeutics," stated Aethlon Chairman and
CEO, Jim Joyce. The news was first reported through a presentation
given by Mr. Joyce at the Exosomes & Circulating Biomarkers 2013
Summit. Mr. Joyce's presentation occurred after the close of market
hours on September 12th.
Aethlon Medical develops therapeutic devices to address unmet
medical needs in cancer, infectious disease, and other life-threatening
conditions. The Company is preparing to launch the first U.S. studies
of the Aethlon Hemopurifier® as a therapy to address hepatitis c virus
(HCV) based on the recent approval of an Investigational Device
Exemption (IDE) by the United States Food and Drug Administration (FDA).
The Hemopurifier® is a first-in-class device that targets the rapid
elimination of viruses and cancer glycopathogens, including
disease-promoting exosomes from circulation.
Exosome Sciences was established by Aethlon to pursue exosome-based strategies to diagnose and monitor the progression of cancer, infectious disease and other life-threatening conditions. ESI's lead product, an Enzyme Linked Lectin Specific Assay (ELLSA) has been validated to identify the presence of exosomes underlying the human immunodeficiency virus (HIV), tuberculosis (TB), and various forms of cancer, including ovarian, melanoma, breast, lymphoma, and colorectal.
Dr. Taylor stated, "I am extremely excited about joining Exosome Sciences as their Chief Scientific Officer. I have been pioneering the field of exosome biology for more than 35 years and believe that exosomes represent the ideal disease marker due to their stability in the peripheral circulation and ability to be multiplexed. Exosome-based diagnostics will not only be used in identification and management of a variety of cancers, but also in other pathologies such as viral infections, pregnancy complications, birth defects, cardiovascular and neurodegenerative diseases. No other platform exhibits their potential for patient stratification and real-time monitoring of therapeutic responses. I have a long history of collaboration with scientists at Aethlon Medical and this opportunity will expand that interaction to bring ELLSA based assays to the clinic."
The release of exosomes by viable cells has been demonstrated in multiple cell types and systems. These nano-sized vesicles are detectable in biologic fluids, including blood, urine, ascites, and pleural fluids. They are essential mediators of normal homeostasis, based on their role in intercellular communication via surface interactions and transfer of macromolecules between cells. Cell injury or transformation is associated with alterations in the cell's exosome production and composition of these exosomes. This aberrant exosome composition can be utilized as surrogate markers of specific disease pathologies. The ESI mission is to advance an exosome-based biomarker platform to diagnose a broad-spectrum of disease conditions as well as monitor disease progression/regression in response to therapy as a means to improve patient management and outcomes. In the oncology field, ESI products will also be positioned to serve as companion diagnostics that determine when to initiate Hemopurifier® therapy or provide real-time monitoring of tumor responses to Hemopurifier® therapy.
About Dr. Taylor
Dr. Taylor discovered and pioneered the field of exosome biology and their role in intercellular communication and immune regulation. He has been in the Department of Obstetrics, Gynecology and Women's Health at the University of Louisville School of Medicine since 1992. Dr. Taylor published the initial article describing circulating tumor exosomes/microvesicles in 1979 (Anal. Biochem. 98:53-59, 1979). The research in his laboratory has primarily focused on the release and consequences of exosomes from gynecologic cancer and lung tumors. Over the past 30+ years, Dr Taylor has pioneered the isolation and characterization of circulating tumor-derived exosomes. His work has focused on characterization of circulating exosomes released by tumor cells for their role in immune regulation and induction of a pro-inflammatory tumor microenvironment. His work has demonstrated that the presence of specific circulating exosomal components have potential use as biomarkers for cancer patients.
About Aethlon Medical
Aethlon Medical creates innovative medical devices that address unmet medical needs in cancer, infectious disease, and other life-threatening conditions. Our Aethlon ADAPT™ System is a revenue-stage technology platform that provides the basis for a new class of devices the rapid, yet selective removal of disease promoting particles from the entire circulatory system. At present, The Aethlon ADAPT™ product pipeline includes the Aethlon Hemopurifier® to address infectious disease and cancer, and a medical device being developed under a 5-year contract with Defense Advanced Research Projects Agency (DARPA) to reduce the incidence of sepsis in combat-injured soldiers. For more information, please visit www.aethlonmedical.com.
Certain statements herein may be forward-looking and involve risks and uncertainties. Such forward-looking statements involve assumptions, known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Aethlon Medical, Inc. to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such potential risks and uncertainties include, without limitation, that the company can successfully protect its intellectual property, that removal of exosomes from the human body will impact or lead to successful treatment of cancer, or that exosomes are the cause of tumor growth and progression, that the FDA will not approve the initiation of the Company's clinical programs or provide market clearance of the company's products, future human studies whether revenue or non-revenue generating of the Aethlon ADAPT™ system or the Aethlon Hemopurifier® as an adjunct therapy to improve patient responsiveness to established cancer or hepatitis C therapies or as a standalone cancer or hepatitis C therapy, the Company's ability to raise capital when needed, the Company's ability to complete the development of its planned products, the Company's ability to manufacture its products either internally or through outside companies and provide its services, the impact of government regulations, patent protection on the Company's proprietary technology, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors. In such instances, actual results could differ materially as a result of a variety of factors, including the risks associated with the effect of changing economic conditions and other risk factors detailed in the Company's Securities and Exchange Commission filings. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.
Contacts:
James A. Joyce
Chairman and CEO
858.459.7800 x301
jj@aethlonmedical.com
Jim Frakes
Chief Financial Officer
858.459.7800 x300
jfrakes@aethlonmedical.com
Marc Robins
877.276.2467
mr@aethlonmedical.com
Published at Investorideas.com newswire
Sign up for the free investor news and stock alerts
http://www.investorideas.com/Resources/Newsletter.asp
Disclaimer / Disclosure : The Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. Disclosure: Investorideas has been compensated by AEMD for news distribution and content publishing: three thousand per month effective June 2013
http://www.investorideas.com/About/Disclaimer.asp
This site is currently compensated by featured companies, news submissions and online advertising.
BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar
Exosome Sciences was established by Aethlon to pursue exosome-based strategies to diagnose and monitor the progression of cancer, infectious disease and other life-threatening conditions. ESI's lead product, an Enzyme Linked Lectin Specific Assay (ELLSA) has been validated to identify the presence of exosomes underlying the human immunodeficiency virus (HIV), tuberculosis (TB), and various forms of cancer, including ovarian, melanoma, breast, lymphoma, and colorectal.
Dr. Taylor stated, "I am extremely excited about joining Exosome Sciences as their Chief Scientific Officer. I have been pioneering the field of exosome biology for more than 35 years and believe that exosomes represent the ideal disease marker due to their stability in the peripheral circulation and ability to be multiplexed. Exosome-based diagnostics will not only be used in identification and management of a variety of cancers, but also in other pathologies such as viral infections, pregnancy complications, birth defects, cardiovascular and neurodegenerative diseases. No other platform exhibits their potential for patient stratification and real-time monitoring of therapeutic responses. I have a long history of collaboration with scientists at Aethlon Medical and this opportunity will expand that interaction to bring ELLSA based assays to the clinic."
The release of exosomes by viable cells has been demonstrated in multiple cell types and systems. These nano-sized vesicles are detectable in biologic fluids, including blood, urine, ascites, and pleural fluids. They are essential mediators of normal homeostasis, based on their role in intercellular communication via surface interactions and transfer of macromolecules between cells. Cell injury or transformation is associated with alterations in the cell's exosome production and composition of these exosomes. This aberrant exosome composition can be utilized as surrogate markers of specific disease pathologies. The ESI mission is to advance an exosome-based biomarker platform to diagnose a broad-spectrum of disease conditions as well as monitor disease progression/regression in response to therapy as a means to improve patient management and outcomes. In the oncology field, ESI products will also be positioned to serve as companion diagnostics that determine when to initiate Hemopurifier® therapy or provide real-time monitoring of tumor responses to Hemopurifier® therapy.
About Dr. Taylor
Dr. Taylor discovered and pioneered the field of exosome biology and their role in intercellular communication and immune regulation. He has been in the Department of Obstetrics, Gynecology and Women's Health at the University of Louisville School of Medicine since 1992. Dr. Taylor published the initial article describing circulating tumor exosomes/microvesicles in 1979 (Anal. Biochem. 98:53-59, 1979). The research in his laboratory has primarily focused on the release and consequences of exosomes from gynecologic cancer and lung tumors. Over the past 30+ years, Dr Taylor has pioneered the isolation and characterization of circulating tumor-derived exosomes. His work has focused on characterization of circulating exosomes released by tumor cells for their role in immune regulation and induction of a pro-inflammatory tumor microenvironment. His work has demonstrated that the presence of specific circulating exosomal components have potential use as biomarkers for cancer patients.
About Aethlon Medical
Aethlon Medical creates innovative medical devices that address unmet medical needs in cancer, infectious disease, and other life-threatening conditions. Our Aethlon ADAPT™ System is a revenue-stage technology platform that provides the basis for a new class of devices the rapid, yet selective removal of disease promoting particles from the entire circulatory system. At present, The Aethlon ADAPT™ product pipeline includes the Aethlon Hemopurifier® to address infectious disease and cancer, and a medical device being developed under a 5-year contract with Defense Advanced Research Projects Agency (DARPA) to reduce the incidence of sepsis in combat-injured soldiers. For more information, please visit www.aethlonmedical.com.
Certain statements herein may be forward-looking and involve risks and uncertainties. Such forward-looking statements involve assumptions, known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Aethlon Medical, Inc. to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such potential risks and uncertainties include, without limitation, that the company can successfully protect its intellectual property, that removal of exosomes from the human body will impact or lead to successful treatment of cancer, or that exosomes are the cause of tumor growth and progression, that the FDA will not approve the initiation of the Company's clinical programs or provide market clearance of the company's products, future human studies whether revenue or non-revenue generating of the Aethlon ADAPT™ system or the Aethlon Hemopurifier® as an adjunct therapy to improve patient responsiveness to established cancer or hepatitis C therapies or as a standalone cancer or hepatitis C therapy, the Company's ability to raise capital when needed, the Company's ability to complete the development of its planned products, the Company's ability to manufacture its products either internally or through outside companies and provide its services, the impact of government regulations, patent protection on the Company's proprietary technology, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors. In such instances, actual results could differ materially as a result of a variety of factors, including the risks associated with the effect of changing economic conditions and other risk factors detailed in the Company's Securities and Exchange Commission filings. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.
Contacts:
James A. Joyce
Chairman and CEO
858.459.7800 x301
jj@aethlonmedical.com
Jim Frakes
Chief Financial Officer
858.459.7800 x300
jfrakes@aethlonmedical.com
Marc Robins
877.276.2467
mr@aethlonmedical.com
Published at Investorideas.com newswire
Sign up for the free investor news and stock alerts
http://www.investorideas.com/Resources/Newsletter.asp
Disclaimer / Disclosure : The Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. Disclosure: Investorideas has been compensated by AEMD for news distribution and content publishing: three thousand per month effective June 2013
http://www.investorideas.com/About/Disclaimer.asp
This site is currently compensated by featured companies, news submissions and online advertising.
BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar
Thursday, September 12, 2013
Apple's (AAPL) Adoption of Biometric Fingerprint Technology Will Play a Key Role in Changing Future of Mobile Security
New York, NY - September 12, 2013 (www.investorideas.com newswire)
Investorideas.com, an investor research portal specializing in investing
ideas in leading sectors including biometric and mobile security stocks
issues a snapshot on key developments in the sector. Apple's (NASDAQ:AAPL) new iPhone 5s launch has everyone talking about biometrics and mobile security.
Apple reported "iPhone 5s introduces Touch ID, an innovative way to
simply and securely unlock your iPhone with just the touch of a finger.
Built into the home button, Touch ID uses a laser cut sapphire crystal,
together with the capacitive touch sensor, to take a high-resolution
image of your fingerprint and intelligently analyze it to provide
accurate readings from any angle. Setting up Touch ID to recognize your
fingerprint is easy, and every time you use it, it gets better. The
Touch ID sensor recognizes the touch of a finger so the sensor is only
activated when needed, preserving battery life. All fingerprint
information is encrypted and stored securely in the Secure Enclave
inside the A7 chip on the iPhone 5s; it’s never stored on Apple servers
or backed up to iCloud®. Touch ID can also be used as a secure way to
approve purchases from the iTunes Store®, App Store or iBooks Store."
Gartner Research projects worldwide mobile payment transactions will exceed $235 billion in 2013, reaching $721 billion in annual transactions with more than 450 million users by 2017. That creates a big opportunity for companies in the mobile security space.
Apple (NASDAQ:AAPL), always known as first to market and an innovator, apparently plans to integrate the fingerprint scanners into the iPhone 6 to address consumer concerns over mobile payment security.
How significant is the biometrics acquisition for Apple? Wells Fargo analyst raised its forecast for Apple based on the biometrics integration.
"We believe investors may be under- appreciating Apple's (NASDAQ:AAPL) Authentec acquisition--specifically the ability to perform secure device-side authentication, which could help open up the mCommerce market and further penetrate the enterprise market," said Wells Fargo analyst Maynard Um.
NXT-ID, Inc. (OTCQB: NXTD),
a new player on the scene in payment security, is launching the Wocket
this fall; a unique technology takes a very different approach: Instead
of replacing the wallet, they are improving it! The Wocket™ reduces the
number of cards in a consumer's wallet while supporting virtually every
payment method currently available at Point-of-Sale (POS) at retailers
around the world including magnetic stripe, EMV/NFC and barcode…all
within a secure vault within a wallet. The company then plans to roll
out a full suite of MobileBio™ technologies for mobile applications
including its 3D Facial recognition technology.
NXT-ID, Inc.'s MobileBio™ facematch™ is a modular facial recognition platform technology that can be applied to a variety of platforms including smartphones, tablets, laptops and desktop computers. Depending on the number of cameras available and level of security desired, facematch™ will use 2D, pseudo 3D or 3D facial recognition algorithms to allow the user access to their device, data, or door. facematch™ supports both 3D and 2D camera devices, supporting various applications such as adding access control to a door or prison to adding superior authentication and/or encryption to a mobile device.
Samsung (KSE:oo5930) is also rumored to be integrating biometrics fingerprint technology in their smartphones and related devices. Samsung previously launched its biometric Face Unlock feature for Galaxy but the technology was easily fooled by photos from its users.
Precise Biometrics AB (PREC) recently had a big run following news of its deal with Fingerprint Cards. Precise Biometrics AB and Fingerprint Cards AB (FPC) announced they have entered into an agreement where FPC will license Precise Biometrics' fingerprint algorithm to further enhance the performance of FPC world leading capacitive sensors. FPC will bundle the algorithm into existing sensor products, primarily targeting mobile phones and tablets. The bundle will further enhance the performance of FPC sensors in terms of accuracy and speed which are important criteria especially in the fast growing mobile and tablet markets.
If Apple integrates biometrics successfully, the world as always, will follow and the race will be on for the search for the best and most secure biometrics technology for mobile users.
About InvestorIdeas.com: Big Ideas for global investors
InvestorIdeas.com is a leader in investor stock research by sector, featuring stock news, commentary and trading alerts in leading sectors including biotech, tech, mining, energy, water, renewable energy, beverage stocks and more.
Research Biometrics Stocks at Investorideas.com stock directory
http://www.investorideas.com/BPS/Stock_List.asp
Sign up for free stock alerts
http://www.investorideas.com/Resources/Newsletter.asp
Published at the Investorideas.com Newswire - Big ideas for Global Investors
Disclaimer/ Disclosure: The Investorideas.com newswire is a third party publisher of news and research as well as creates original content as a news source. Original content created by investorideas is protected by copyright laws other than syndication rights. Investorideas is a news source on Google news and Linkedintoday plus hundreds of syndication partners. Our site does not make recommendations for purchases or sale of stocks or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated by featured companies, news submissions, content marketing and online advertising. Contact each company directly for press release questions. Disclosure is posted on each release if required but otherwise the news was not compensated for and is published for the sole interest of our readers. Disclosure: Investorideas has been compensated by NXTD: five thousand per month plus 144 shares.
More info : http://www.investorideas.com/About/Disclaimer.asp
BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each country.
800-665-0411 - or 212-822-8842 Source - www.Investorideas.com
Gartner Research projects worldwide mobile payment transactions will exceed $235 billion in 2013, reaching $721 billion in annual transactions with more than 450 million users by 2017. That creates a big opportunity for companies in the mobile security space.
Apple (NASDAQ:AAPL), always known as first to market and an innovator, apparently plans to integrate the fingerprint scanners into the iPhone 6 to address consumer concerns over mobile payment security.
How significant is the biometrics acquisition for Apple? Wells Fargo analyst raised its forecast for Apple based on the biometrics integration.
"We believe investors may be under- appreciating Apple's (NASDAQ:AAPL) Authentec acquisition--specifically the ability to perform secure device-side authentication, which could help open up the mCommerce market and further penetrate the enterprise market," said Wells Fargo analyst Maynard Um.
NXT-ID, Inc. (OTCQB: NXTD),
a new player on the scene in payment security, is launching the Wocket
this fall; a unique technology takes a very different approach: Instead
of replacing the wallet, they are improving it! The Wocket™ reduces the
number of cards in a consumer's wallet while supporting virtually every
payment method currently available at Point-of-Sale (POS) at retailers
around the world including magnetic stripe, EMV/NFC and barcode…all
within a secure vault within a wallet. The company then plans to roll
out a full suite of MobileBio™ technologies for mobile applications
including its 3D Facial recognition technology.NXT-ID, Inc.'s MobileBio™ facematch™ is a modular facial recognition platform technology that can be applied to a variety of platforms including smartphones, tablets, laptops and desktop computers. Depending on the number of cameras available and level of security desired, facematch™ will use 2D, pseudo 3D or 3D facial recognition algorithms to allow the user access to their device, data, or door. facematch™ supports both 3D and 2D camera devices, supporting various applications such as adding access control to a door or prison to adding superior authentication and/or encryption to a mobile device.
Samsung (KSE:oo5930) is also rumored to be integrating biometrics fingerprint technology in their smartphones and related devices. Samsung previously launched its biometric Face Unlock feature for Galaxy but the technology was easily fooled by photos from its users.
Precise Biometrics AB (PREC) recently had a big run following news of its deal with Fingerprint Cards. Precise Biometrics AB and Fingerprint Cards AB (FPC) announced they have entered into an agreement where FPC will license Precise Biometrics' fingerprint algorithm to further enhance the performance of FPC world leading capacitive sensors. FPC will bundle the algorithm into existing sensor products, primarily targeting mobile phones and tablets. The bundle will further enhance the performance of FPC sensors in terms of accuracy and speed which are important criteria especially in the fast growing mobile and tablet markets.
If Apple integrates biometrics successfully, the world as always, will follow and the race will be on for the search for the best and most secure biometrics technology for mobile users.
About InvestorIdeas.com: Big Ideas for global investors
InvestorIdeas.com is a leader in investor stock research by sector, featuring stock news, commentary and trading alerts in leading sectors including biotech, tech, mining, energy, water, renewable energy, beverage stocks and more.
Research Biometrics Stocks at Investorideas.com stock directory
http://www.investorideas.com/BPS/Stock_List.asp
Sign up for free stock alerts
http://www.investorideas.com/Resources/Newsletter.asp
Published at the Investorideas.com Newswire - Big ideas for Global Investors
Disclaimer/ Disclosure: The Investorideas.com newswire is a third party publisher of news and research as well as creates original content as a news source. Original content created by investorideas is protected by copyright laws other than syndication rights. Investorideas is a news source on Google news and Linkedintoday plus hundreds of syndication partners. Our site does not make recommendations for purchases or sale of stocks or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated by featured companies, news submissions, content marketing and online advertising. Contact each company directly for press release questions. Disclosure is posted on each release if required but otherwise the news was not compensated for and is published for the sole interest of our readers. Disclosure: Investorideas has been compensated by NXTD: five thousand per month plus 144 shares.
More info : http://www.investorideas.com/About/Disclaimer.asp
BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each country.
800-665-0411 - or 212-822-8842 Source - www.Investorideas.com
Medical Technology Breaking News: Aethlon Medical (OTCQB: AEMD) Announces Launch of Exosome Sciences Subsidiary
SAN DIEGO - September 12, 2013 (Investorideas.com newswire) Aethlon Medical, Inc. (OTCBB:AEMD),
today announced the formal launch of Exosome Sciences, Inc. (ESI), a
wholly-owned subsidiary previously established by Aethlon to pursue
exosome-based strategies to diagnose and monitor the progression of
cancer, infectious disease and other life-threatening conditions.
Exosomes produced by diseased cells represent an optimal diagnostic
target as they are shed into bodily fluids such as urine and blood where
they can be easily accessed. Exosomes transport specific disease-origin
markers that provide the basis for ESI to establish non-invasive liquid
biopsies to diagnose and monitor a wide-range of disease conditions.
Aethlon Chairman and CEO, Jim Joyce stated, "As a therapeutic
organization, our primary focus is the clinical advancement and future
commercialization of the Aethlon Hemopurifer® in the United States and
abroad. With this mind, our objective with ESI is to transform a
currently dormant and unvalued diagnostic asset into a stand-alone
organization that contributes measurable asset value to Aethlon
shareholders, yet does not dilute our team's focus away from advancing
first-in-class therapeutic devices. It also became clear that the launch
of ESI might allow us to leverage recent valuations that have been
awarded to molecular diagnostic organizations with novel technology
strategies."
Aethlon disclosed that ESI's research facility is being established within a CLIA certified laboratory located in Langhorne, Pennsylvania. The facility is adjacent to the Philadelphia/New Jersey I-95 corridor, which is the home for numerous U.S. biopharmaceutical organizations, including Merck and Johnson & Johnson. The introduction of key ESI researchers who will lead the development and commercialization of next-generation diagnostics will occur through follow-on disclosures.
At present, Aethlon is preparing to launch the first U.S. studies of the Hemopurifier® as a therapy to address hepatitis c virus (HCV) based on the recent approval of an Investigational Device Exemption (IDE) by the United States Food and Drug Administration (FDA). The Hemopurifier is a first-in-class device that targets the rapid elimination of infectious disease and cancer glycopathogens, including exosomes from circulation. Exosomes enhance disease progression of viral infections and in cancer trigger apoptosis of immune cells and have been reported to facilitate tumor growth, metastasis, and the development of drug resistance.
Aethlon will contribute diagnostic related technology to ESI, including the Enzyme Linked Lectin Specific Assay (ELLSA), which has been validated to identify the presence of exosomes underlying the human immunodeficiency virus (HIV), tuberculosis (TB), and various forms of cancer, including ovarian, melanoma, breast, lymphoma, and colorectal. ELLSA was originally created by Aethlon researchers as a tool to help validate the ability of the Hemopurifier® to capture tumor-secreted exosomes. At the time, effective tools to isolate and quantify exosomes did not exist as few labs conducted exosome research. Since then, an increased understanding of the role of exosomes underlying a wide-range of disease conditions has created a demand for related diagnostic products. As part of the relationship, ESI has agreed to assign any therapeutic related discoveries back to Aethlon Medical. Beyond the potential for future technology advances by ESI researchers, ESI may also in-license related diagnostic IP from collaborative research partners.
The release of exosomes by viable cells has been demonstrated in multiple cell types and systems. These nano-sized vesicles are detectable in biologic fluids, including blood, urine, ascites, and pleural fluids. They are essential mediators of normal homeostasis, based on their role in intercellular communication via surface interactions and transfer of macromolecules between cells. Cell injury or transformation is associated with alterations in the cell's exosome production and composition of these exosomes. This aberrant exosome composition can be utilized as surrogate markers of specific disease pathologies. The ESI mission is to advance an exosome-based biomarker platform to diagnose a broad-spectrum of disease conditions as well as monitor disease progression/regression in response to therapy as a means to improve patient management and outcomes. In the oncology field, ESI products will also be positioned to serve as companion diagnostics that determine when to initiate Hemopurifier® therapy or provide real-time monitoring of tumor responses to Hemopurifier® therapy.
About Aethlon Medical
Aethlon Medical creates innovative medical devices that address unmet medical needs in cancer, infectious disease, and other life-threatening conditions. Our Aethlon ADAPT™ System is a revenue-stage technology platform that provides the basis for a new class of devices the rapid, yet selective removal of disease promoting particles from the entire circulatory system. At present, The Aethlon ADAPT™ product pipeline includes the Aethlon Hemopurifier® to address infectious disease and cancer, and a medical device being developed under a 5-year contract with Defense Advanced Research Projects Agency (DARPA) to reduce the incidence of sepsis in combat-injured soldiers. For more information, please visit www.aethlonmedical.com.
Certain statements herein may be forward-looking and involve risks and uncertainties. Such forward-looking statements involve assumptions, known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Aethlon Medical, Inc. to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such potential risks and uncertainties include, without limitation, that the company can successfully protect its intellectual property, that removal of exosomes from the human body will impact or lead to successful treatment of cancer, or that exosomes are the cause of tumor growth and progression, that the FDA will not approve the initiation of the Company's clinical programs or provide market clearance of the company's products, future human studies whether revenue or non-revenue generating of the Aethlon ADAPT™ system or the Aethlon Hemopurifier® as an adjunct therapy to improve patient responsiveness to established cancer or hepatitis C therapies or as a standalone cancer or hepatitis C therapy, the Company's ability to raise capital when needed, the Company's ability to complete the development of its planned products, the Company's ability to manufacture its products either internally or through outside companies and provide its services, the impact of government regulations, patent protection on the Company's proprietary technology, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors. In such instances, actual results could differ materially as a result of a variety of factors, including the risks associated with the effect of changing economic conditions and other risk factors detailed in the Company's Securities and Exchange Commission filings. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.
Contacts:
James A. Joyce
Chairman and CEO
858.459.7800 x301
jj@aethlonmedical.com
Jim Frakes
Chief Financial Officer
858.459.7800 x300
jfrakes@aethlonmedical.com
Marc Robins
877.276.2467
mr@aethlonmedical.com
Published at Investorideas.com newswire
Sign up for the free investor news and stock alerts
http://www.investorideas.com/Resources/Newsletter.asp
Disclaimer / Disclosure : The Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. Disclosure: Investorideas has been compensated by AEMD for news distribution and content publishing: three thousand per month effective June 2013
http://www.investorideas.com/About/Disclaimer.asp
This site is currently compensated by featured companies, news submissions and online advertising.
BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar
Aethlon disclosed that ESI's research facility is being established within a CLIA certified laboratory located in Langhorne, Pennsylvania. The facility is adjacent to the Philadelphia/New Jersey I-95 corridor, which is the home for numerous U.S. biopharmaceutical organizations, including Merck and Johnson & Johnson. The introduction of key ESI researchers who will lead the development and commercialization of next-generation diagnostics will occur through follow-on disclosures.
At present, Aethlon is preparing to launch the first U.S. studies of the Hemopurifier® as a therapy to address hepatitis c virus (HCV) based on the recent approval of an Investigational Device Exemption (IDE) by the United States Food and Drug Administration (FDA). The Hemopurifier is a first-in-class device that targets the rapid elimination of infectious disease and cancer glycopathogens, including exosomes from circulation. Exosomes enhance disease progression of viral infections and in cancer trigger apoptosis of immune cells and have been reported to facilitate tumor growth, metastasis, and the development of drug resistance.
Aethlon will contribute diagnostic related technology to ESI, including the Enzyme Linked Lectin Specific Assay (ELLSA), which has been validated to identify the presence of exosomes underlying the human immunodeficiency virus (HIV), tuberculosis (TB), and various forms of cancer, including ovarian, melanoma, breast, lymphoma, and colorectal. ELLSA was originally created by Aethlon researchers as a tool to help validate the ability of the Hemopurifier® to capture tumor-secreted exosomes. At the time, effective tools to isolate and quantify exosomes did not exist as few labs conducted exosome research. Since then, an increased understanding of the role of exosomes underlying a wide-range of disease conditions has created a demand for related diagnostic products. As part of the relationship, ESI has agreed to assign any therapeutic related discoveries back to Aethlon Medical. Beyond the potential for future technology advances by ESI researchers, ESI may also in-license related diagnostic IP from collaborative research partners.
The release of exosomes by viable cells has been demonstrated in multiple cell types and systems. These nano-sized vesicles are detectable in biologic fluids, including blood, urine, ascites, and pleural fluids. They are essential mediators of normal homeostasis, based on their role in intercellular communication via surface interactions and transfer of macromolecules between cells. Cell injury or transformation is associated with alterations in the cell's exosome production and composition of these exosomes. This aberrant exosome composition can be utilized as surrogate markers of specific disease pathologies. The ESI mission is to advance an exosome-based biomarker platform to diagnose a broad-spectrum of disease conditions as well as monitor disease progression/regression in response to therapy as a means to improve patient management and outcomes. In the oncology field, ESI products will also be positioned to serve as companion diagnostics that determine when to initiate Hemopurifier® therapy or provide real-time monitoring of tumor responses to Hemopurifier® therapy.
About Aethlon Medical
Aethlon Medical creates innovative medical devices that address unmet medical needs in cancer, infectious disease, and other life-threatening conditions. Our Aethlon ADAPT™ System is a revenue-stage technology platform that provides the basis for a new class of devices the rapid, yet selective removal of disease promoting particles from the entire circulatory system. At present, The Aethlon ADAPT™ product pipeline includes the Aethlon Hemopurifier® to address infectious disease and cancer, and a medical device being developed under a 5-year contract with Defense Advanced Research Projects Agency (DARPA) to reduce the incidence of sepsis in combat-injured soldiers. For more information, please visit www.aethlonmedical.com.
Certain statements herein may be forward-looking and involve risks and uncertainties. Such forward-looking statements involve assumptions, known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Aethlon Medical, Inc. to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such potential risks and uncertainties include, without limitation, that the company can successfully protect its intellectual property, that removal of exosomes from the human body will impact or lead to successful treatment of cancer, or that exosomes are the cause of tumor growth and progression, that the FDA will not approve the initiation of the Company's clinical programs or provide market clearance of the company's products, future human studies whether revenue or non-revenue generating of the Aethlon ADAPT™ system or the Aethlon Hemopurifier® as an adjunct therapy to improve patient responsiveness to established cancer or hepatitis C therapies or as a standalone cancer or hepatitis C therapy, the Company's ability to raise capital when needed, the Company's ability to complete the development of its planned products, the Company's ability to manufacture its products either internally or through outside companies and provide its services, the impact of government regulations, patent protection on the Company's proprietary technology, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors. In such instances, actual results could differ materially as a result of a variety of factors, including the risks associated with the effect of changing economic conditions and other risk factors detailed in the Company's Securities and Exchange Commission filings. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.
Contacts:
James A. Joyce
Chairman and CEO
858.459.7800 x301
jj@aethlonmedical.com
Jim Frakes
Chief Financial Officer
858.459.7800 x300
jfrakes@aethlonmedical.com
Marc Robins
877.276.2467
mr@aethlonmedical.com
Published at Investorideas.com newswire
Sign up for the free investor news and stock alerts
http://www.investorideas.com/Resources/Newsletter.asp
Disclaimer / Disclosure : The Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. Disclosure: Investorideas has been compensated by AEMD for news distribution and content publishing: three thousand per month effective June 2013
http://www.investorideas.com/About/Disclaimer.asp
This site is currently compensated by featured companies, news submissions and online advertising.
BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar
Wednesday, September 11, 2013
The Growing Portable Power Generation Market: From Diesel to Natural Gas, Fuel Cells to Solar, the Global Demand is on the Rise
New York, NY - September 11, 2013 (Investorideas.com renewable energy
stocks newswire) Investorideas.com, an investor research portal
specializing in sector research for independent investors, including
renewable energy stocks issues a sector snapshot for portable power
generation stocks and the growing global market opportunity.
Diesel and gas power generators (Gensets) represent a bullish
growing global industry according to research firm GlobalData,
predicting the market will nearly double from $12 billion in 2011 to
some $22.3 billion by 2020. GlobalData also says growth is being driven
by an increasing need for safe and reliable off-grid power in numerous
end markets.
Key growth areas to watch are India and China, with India growing from $1.2 billion to $2.54 billion by 2020 and China growing from $2.4 billion to nearly $5.5 billion by 2020.
According to an article in Forbes in late August following the report, "The projected market growth will likely benefit major industrial equipment vendors like Caterpillar (NYSE:CAT ) and Cummins (NYSE:CMI ) with a strong position in the distributed power space. But smaller companies like Scotland’s Aggreko with experience working in developing countries will also benefit.”
Briggs & Stratton Corporation (NYSE: BGG), with its wholly owned subsidiary that is North America's number one marketer of portable generators is also poised to benefit in the industry growth. The Company just released a news and media alert September 3rd entitled, "Portable, Standby Generators Play Powerful Role in National Preparedness Month."
As the market grows, energy efficiency and the role of renewable energy in the mix will also be key. From solar to fuel cells, new technology that represents a greener alternative will take a leading role.
Pike Research says that the current period of product development will lead to commercialization for portable fuel cells at an increasingly larger scale beginning in the 2015 timeframe.
A smaller player in the sector, Powerdyne International Inc. (OTCBB:PWDY) is aiming to meet greener standards while still being able to utilize traditional fuels. The company recently announced that it is expanding its reach in the renewable energy market through strategic relationships such as the recently formed agreement with Turning Mill Energy, of Sandwich, Massachusetts, a solar and wind company’.
The Powerdyne Genset uses a completely different type of engine that is small, powerful, light weight, portable, air cooled, runs on almost any gaseous fuel, environmentally green, and is easily maintained and serviced.
Dale Euga, President of Powerdyne International, Inc., stated, "Our companies will work together to offer large electrical users independent power generation, on-site. This lowers the user's cost of electricity without incurring expensive capital equipment costs."
Mr. Euga noted that, "The need for distributed electricity, using integrated and balanced technologies, is the key to continuing worldwide commercial growth."
Forbes article - http://www.forbes.com/sites/williampentland/2013/08/08/generator-demand-goes-gangbusters/
About InvestorIdeas.com:
InvestorIdeas.com is a leader in investor stock research by sector, featuring stock news, commentary and trading alerts in leading sectors including biotech, tech, mining, energy, water, renewable energy, beverage stocks and more.
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Follow Investorideas.com News on Linkedin.com/today at http://www.linkedin.com/today/investorideas.com
Sign up for renewable energy stock alerts http://www.investorideas.com/Resources/Newsletter.asp
Become an Investorideas.com Member and access our 14 online stock directories 24/7 - tech, social media stocks, biotech stocks, water, renewable energy stocks, mining stocks and more…
http://www.investorideas.com/membership/
Disclaimer/ Disclosure: The Investorideas.com newswire is a third party publisher of news and research as well as creates original content as a news source. Original content created by investorideas is protected by copyright laws other than syndication rights. Investorideas is a news source on Google news and Linkedintoday plus hundreds of syndication partners. Our site does not make recommendations for purchases or sale of stocks or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated by featured companies, news submissions, content marketing and online advertising. Contact each company directly for press release questions. Disclosure is posted on each release if required but otherwise the news was not compensated for and is published for the sole interest of our readers. More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp. Disclosure: Investorideas.com newswire has been compensated two thousand dollars for one month of news and content distribution. BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each country.
800-665-0411 - Source - www.Investorideas.com
Key growth areas to watch are India and China, with India growing from $1.2 billion to $2.54 billion by 2020 and China growing from $2.4 billion to nearly $5.5 billion by 2020.
According to an article in Forbes in late August following the report, "The projected market growth will likely benefit major industrial equipment vendors like Caterpillar (NYSE:CAT ) and Cummins (NYSE:CMI ) with a strong position in the distributed power space. But smaller companies like Scotland’s Aggreko with experience working in developing countries will also benefit.”
Briggs & Stratton Corporation (NYSE: BGG), with its wholly owned subsidiary that is North America's number one marketer of portable generators is also poised to benefit in the industry growth. The Company just released a news and media alert September 3rd entitled, "Portable, Standby Generators Play Powerful Role in National Preparedness Month."
As the market grows, energy efficiency and the role of renewable energy in the mix will also be key. From solar to fuel cells, new technology that represents a greener alternative will take a leading role.
Pike Research says that the current period of product development will lead to commercialization for portable fuel cells at an increasingly larger scale beginning in the 2015 timeframe.
A smaller player in the sector, Powerdyne International Inc. (OTCBB:PWDY) is aiming to meet greener standards while still being able to utilize traditional fuels. The company recently announced that it is expanding its reach in the renewable energy market through strategic relationships such as the recently formed agreement with Turning Mill Energy, of Sandwich, Massachusetts, a solar and wind company’.
The Powerdyne Genset uses a completely different type of engine that is small, powerful, light weight, portable, air cooled, runs on almost any gaseous fuel, environmentally green, and is easily maintained and serviced.
Dale Euga, President of Powerdyne International, Inc., stated, "Our companies will work together to offer large electrical users independent power generation, on-site. This lowers the user's cost of electricity without incurring expensive capital equipment costs."
Mr. Euga noted that, "The need for distributed electricity, using integrated and balanced technologies, is the key to continuing worldwide commercial growth."
Forbes article - http://www.forbes.com/sites/williampentland/2013/08/08/generator-demand-goes-gangbusters/
About InvestorIdeas.com:
InvestorIdeas.com is a leader in investor stock research by sector, featuring stock news, commentary and trading alerts in leading sectors including biotech, tech, mining, energy, water, renewable energy, beverage stocks and more.
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Follow Investorideas.com News on Linkedin.com/today at http://www.linkedin.com/today/investorideas.com
Sign up for renewable energy stock alerts http://www.investorideas.com/Resources/Newsletter.asp
Become an Investorideas.com Member and access our 14 online stock directories 24/7 - tech, social media stocks, biotech stocks, water, renewable energy stocks, mining stocks and more…
http://www.investorideas.com/membership/
Disclaimer/ Disclosure: The Investorideas.com newswire is a third party publisher of news and research as well as creates original content as a news source. Original content created by investorideas is protected by copyright laws other than syndication rights. Investorideas is a news source on Google news and Linkedintoday plus hundreds of syndication partners. Our site does not make recommendations for purchases or sale of stocks or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated by featured companies, news submissions, content marketing and online advertising. Contact each company directly for press release questions. Disclosure is posted on each release if required but otherwise the news was not compensated for and is published for the sole interest of our readers. More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp. Disclosure: Investorideas.com newswire has been compensated two thousand dollars for one month of news and content distribution. BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each country.
800-665-0411 - Source - www.Investorideas.com
Tuesday, September 10, 2013
As Apple (APPL) does others will Follow: Apple's Biometric Acquisition Will Play a Key Role in Changing the Face of Mobile Security
New York, NY - September 10, 2013 (www.investorideas.com newswire)
Investorideas.com, an investor research portal specializing in investing
ideas in leading sectors including biometric and mobile security stocks
issues a snapshot on key developments in the sector. Apple's (NASDAQ:AAPL)
acquisition of mobile security company AuthenTec for over $350 million
has Wall Street and the industry buzzing about how biometric technology
in smartphones will impact the global m-commerce market.
Gartner Research projects worldwide mobile payment transactions
will exceed $235 billion in 2013, reaching $721 billion in annual
transactions with more than 450 million users by 2017. That creates a
big opportunity for companies in the mobile security space.
Apple (NASDAQ:AAPL), always known as first to market and an innovator, apparently plans to integrate the fingerprint scanners into the iPhone 6 to address consumer concerns over mobile payment security.
How significant is the biometrics acquisition for Apple? Wells Fargo analyst raised its forecast for Apple based on the biometrics integration.
"We believe investors may be under- appreciating Apple's (NASDAQ:AAPL) Authentec acquisition--specifically the ability to perform secure device-side authentication, which could help open up the mCommerce market and further penetrate the enterprise market," said Wells Fargo analyst Maynard Um.
NXT-ID, Inc. (OTCQB: NXTD),
a new player on the scene in payment security, is launching the Wocket
this fall; a unique technology takes a very different approach: Instead
of replacing the wallet, they are improving it! The Wocket™ reduces the
number of cards in a consumer's wallet while supporting virtually every
payment method currently available at Point-of-Sale (POS) at retailers
around the world including magnetic stripe, EMV/NFC and barcode…all
within a secure vault within a wallet. The company then plans to roll
out a full suite of MobileBio™ technologies for mobile applications
including its 3D Facial recognition technology.
NXT-ID, Inc.'s MobileBio™ facematch™ is a modular facial recognition platform technology that can be applied to a variety of platforms including smartphones, tablets, laptops and desktop computers. Depending on the number of cameras available and level of security desired, facematch™ will use 2D, pseudo 3D or 3D facial recognition algorithms to allow the user access to their device, data, or door. facematch™ supports both 3D and 2D camera devices, supporting various applications such as adding access control to a door or prison to adding superior authentication and/or encryption to a mobile device.
Samsung (KSE:oo5930) is also rumored to be integrating biometrics fingerprint technology in their smartphones and related devices. Samsung previously launched its biometric Face Unlock feature for Galaxy but the technology was easily fooled by photos from its users.
Precise Biometrics AB (PREC) recently had a big run following news of its deal with Fingerprint Cards. Precise Biometrics AB and Fingerprint Cards AB (FPC) announced they have entered into an agreement where FPC will license Precise Biometrics' fingerprint algorithm to further enhance the performance of FPC world leading capacitive sensors. FPC will bundle the algorithm into existing sensor products, primarily targeting mobile phones and tablets. The bundle will further enhance the performance of FPC sensors in terms of accuracy and speed which are important criteria especially in the fast growing mobile and tablet markets.
If Apple integrates biometrics successfully, the world as always, will follow and the race will be on for the search for the best and most secure biometrics technology for mobile users.
About InvestorIdeas.com: Big Ideas for global investors
InvestorIdeas.com is a leader in investor stock research by sector, featuring stock news, commentary and trading alerts in leading sectors including biotech, tech, mining, energy, water, renewable energy, beverage stocks and more.
Research Biometrics Stocks at Investorideas.com stock directory
http://www.investorideas.com/BPS/Stock_List.asp
Sign up for free stock alerts
http://www.investorideas.com/Resources/Newsletter.asp
Published at the Investorideas.com Newswire - Big ideas for Global Investors
Disclaimer/ Disclosure: The Investorideas.com newswire is a third party publisher of news and research as well as creates original content as a news source. Original content created by investorideas is protected by copyright laws other than syndication rights. Investorideas is a news source on Google news and Linkedintoday plus hundreds of syndication partners. Our site does not make recommendations for purchases or sale of stocks or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated by featured companies, news submissions, content marketing and online advertising. Contact each company directly for press release questions. Disclosure is posted on each release if required but otherwise the news was not compensated for and is published for the sole interest of our readers. Disclosure: Investorideas has been compensated by NXTD: five thousand per month plus 144 shares.
More info : http://www.investorideas.com/About/Disclaimer.asp
BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each country.
800-665-0411 - or 212-822-8842 Source - www.Investorideas.com
Apple (NASDAQ:AAPL), always known as first to market and an innovator, apparently plans to integrate the fingerprint scanners into the iPhone 6 to address consumer concerns over mobile payment security.
How significant is the biometrics acquisition for Apple? Wells Fargo analyst raised its forecast for Apple based on the biometrics integration.
"We believe investors may be under- appreciating Apple's (NASDAQ:AAPL) Authentec acquisition--specifically the ability to perform secure device-side authentication, which could help open up the mCommerce market and further penetrate the enterprise market," said Wells Fargo analyst Maynard Um.
NXT-ID, Inc. (OTCQB: NXTD),
a new player on the scene in payment security, is launching the Wocket
this fall; a unique technology takes a very different approach: Instead
of replacing the wallet, they are improving it! The Wocket™ reduces the
number of cards in a consumer's wallet while supporting virtually every
payment method currently available at Point-of-Sale (POS) at retailers
around the world including magnetic stripe, EMV/NFC and barcode…all
within a secure vault within a wallet. The company then plans to roll
out a full suite of MobileBio™ technologies for mobile applications
including its 3D Facial recognition technology.NXT-ID, Inc.'s MobileBio™ facematch™ is a modular facial recognition platform technology that can be applied to a variety of platforms including smartphones, tablets, laptops and desktop computers. Depending on the number of cameras available and level of security desired, facematch™ will use 2D, pseudo 3D or 3D facial recognition algorithms to allow the user access to their device, data, or door. facematch™ supports both 3D and 2D camera devices, supporting various applications such as adding access control to a door or prison to adding superior authentication and/or encryption to a mobile device.
Samsung (KSE:oo5930) is also rumored to be integrating biometrics fingerprint technology in their smartphones and related devices. Samsung previously launched its biometric Face Unlock feature for Galaxy but the technology was easily fooled by photos from its users.
Precise Biometrics AB (PREC) recently had a big run following news of its deal with Fingerprint Cards. Precise Biometrics AB and Fingerprint Cards AB (FPC) announced they have entered into an agreement where FPC will license Precise Biometrics' fingerprint algorithm to further enhance the performance of FPC world leading capacitive sensors. FPC will bundle the algorithm into existing sensor products, primarily targeting mobile phones and tablets. The bundle will further enhance the performance of FPC sensors in terms of accuracy and speed which are important criteria especially in the fast growing mobile and tablet markets.
If Apple integrates biometrics successfully, the world as always, will follow and the race will be on for the search for the best and most secure biometrics technology for mobile users.
About InvestorIdeas.com: Big Ideas for global investors
InvestorIdeas.com is a leader in investor stock research by sector, featuring stock news, commentary and trading alerts in leading sectors including biotech, tech, mining, energy, water, renewable energy, beverage stocks and more.
Research Biometrics Stocks at Investorideas.com stock directory
http://www.investorideas.com/BPS/Stock_List.asp
Sign up for free stock alerts
http://www.investorideas.com/Resources/Newsletter.asp
Published at the Investorideas.com Newswire - Big ideas for Global Investors
Disclaimer/ Disclosure: The Investorideas.com newswire is a third party publisher of news and research as well as creates original content as a news source. Original content created by investorideas is protected by copyright laws other than syndication rights. Investorideas is a news source on Google news and Linkedintoday plus hundreds of syndication partners. Our site does not make recommendations for purchases or sale of stocks or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated by featured companies, news submissions, content marketing and online advertising. Contact each company directly for press release questions. Disclosure is posted on each release if required but otherwise the news was not compensated for and is published for the sole interest of our readers. Disclosure: Investorideas has been compensated by NXTD: five thousand per month plus 144 shares.
More info : http://www.investorideas.com/About/Disclaimer.asp
BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each country.
800-665-0411 - or 212-822-8842 Source - www.Investorideas.com
Friday, September 06, 2013
Australian based Jenepe Asset Management launches new IPO fund
September 6, 2013 (www.investorideas.com newswire) Australian based
investment house Jenepe Asset Management, in joint venture with London
based IPO Capital Partners, has launched a fund targeting new listing
opportunities.
The Certified Investment Management Analyst (CIMA) regulated fund,
Jenepe IPO Capital Fund S.P., domiciled offshore in the Cayman Islands,
will be managed by Nicholas Pereza-Mathews and will take positions in
range of financial instruments focused on the Pre-IPO sector.
Mr Pereza-Mathews, who has over twenty years' experience in global markets and funds management working in London and Australasia, previously managed the Australian Natural Resources Fund, a top performing fund within its class achieving sound Alpha returns under his stewardship.
Mr Pereza-Mathews says the IPO sector has vast potential for growth given there has been a lack of capital commitment available for new listings since the GFC, with IPO's falling off dramatically each year.
"Our process is driven by performance and not asset gathering, aiming to provide capital appreciation over the medium term," Mr Pereza-Mathews says.
"As a seed to IPO fund we will be able to invest at an early stage of a companies intended listing which should generate significant returns when the companies complete a stock exchange listing."
"This is achieved by investing in a diversified range of securities ranging from early stage growth companies through to established companies seeking to list on a global recognised investment exchange within a 12 month period."
The fund's investment process is driven by a security selection process based on ascertaining the suitability of an investment through an in-depth assessment of commercial and financial aspects of each opportunity, screened by Jenepes' Investment Committee due diligence process.
IPO Capital Partner's Clifford Giles says we are excited about the new opportunities presented with the Jenepe IPO Capital Fund and Jenepe Asset Management team.
"We look forward to adding value to the team from our London base as we approach our next growth phase."
Mr Pereza-Mathews says once identified, opportunities are screened to ensure they are of an investment grade.
"A full assessment of the proposed investment is completed to establish whether the business is of a suitable quality and attractively priced," Mr Pereza-Mathews says.
"Jenepe is a focused investment manager seeking to provide superior investment returns for institutional and sophisticated investors, managed by an experienced team with an established track record of investing in seed and IPOs."
Jenepe also offers Global Markets and Foreign Exchange dealing and Capital Raising for sophisticated and institutional investors, with the aim to deliver profitable outcomes for clients from the one provider.
For more information go to www.jenepe.com
Media enquiries contact
Bruce Nelson on +61 423 403 449
About Jenepé
Jenepé Group is a boutique investment house which has office locations in Melbourne, Perth, Gold Coast and London offering globally a range of corporate financial services: including Funds Management, Global Markets wholesale brokerage, Forex trading, Stock Exchange listings, Capital Raising, Corporate Communications, Corporate Compliance Services and Prospectus Preparation.
Mr Pereza-Mathews, who has over twenty years' experience in global markets and funds management working in London and Australasia, previously managed the Australian Natural Resources Fund, a top performing fund within its class achieving sound Alpha returns under his stewardship.
Mr Pereza-Mathews says the IPO sector has vast potential for growth given there has been a lack of capital commitment available for new listings since the GFC, with IPO's falling off dramatically each year.
"Our process is driven by performance and not asset gathering, aiming to provide capital appreciation over the medium term," Mr Pereza-Mathews says.
"As a seed to IPO fund we will be able to invest at an early stage of a companies intended listing which should generate significant returns when the companies complete a stock exchange listing."
"This is achieved by investing in a diversified range of securities ranging from early stage growth companies through to established companies seeking to list on a global recognised investment exchange within a 12 month period."
The fund's investment process is driven by a security selection process based on ascertaining the suitability of an investment through an in-depth assessment of commercial and financial aspects of each opportunity, screened by Jenepes' Investment Committee due diligence process.
IPO Capital Partner's Clifford Giles says we are excited about the new opportunities presented with the Jenepe IPO Capital Fund and Jenepe Asset Management team.
"We look forward to adding value to the team from our London base as we approach our next growth phase."
Mr Pereza-Mathews says once identified, opportunities are screened to ensure they are of an investment grade.
"A full assessment of the proposed investment is completed to establish whether the business is of a suitable quality and attractively priced," Mr Pereza-Mathews says.
"Jenepe is a focused investment manager seeking to provide superior investment returns for institutional and sophisticated investors, managed by an experienced team with an established track record of investing in seed and IPOs."
Jenepe also offers Global Markets and Foreign Exchange dealing and Capital Raising for sophisticated and institutional investors, with the aim to deliver profitable outcomes for clients from the one provider.
For more information go to www.jenepe.com
Media enquiries contact
Bruce Nelson on +61 423 403 449
About Jenepé
Jenepé Group is a boutique investment house which has office locations in Melbourne, Perth, Gold Coast and London offering globally a range of corporate financial services: including Funds Management, Global Markets wholesale brokerage, Forex trading, Stock Exchange listings, Capital Raising, Corporate Communications, Corporate Compliance Services and Prospectus Preparation.
Thursday, September 05, 2013
Mining Stock Alert: SilverCrest (TSX.V: SVL) (NYSE MKT: SVLC) Reports Additional Drill Results at Santa Elena Mine; Another Discovery and More High Grade Intercepts, 15 metres @ 4 gpt Au and 243 gpt Ag including 2 metres @ 17.5 gpt Au and 664 gpt Ag
Vancouver, British Columbia - September 5, 2013 (Investorideas.com Mining Stocks Newswire) SilverCrest Mines Inc. (TSX.V:SVL) ( NYSE MKT: SVLC)
is pleased to announce further results of delineation drilling at the
Santa Elena Mine in Sonora, Mexico. A total of 181 core and RVC holes
were completed in this program of which 134 holes were utilized in the
recently announced “Santa Elena Pre-Feasibility Study and Update Reserve
Technical Report” (Technical Report). Results for the remaining 47
holes reported in this news release were not available for inclusion in
the revised Reserves and Resources for the Technical Report. The results
show further expansion of the Santa Elena Deposit which is still open
latterly and to depth (see attached Figures). Several of these reported
holes identified additional high grade intercepts, expanded the recently
discovered El Cholugo and El Cholugo Dos Zones, and also discovered a
new zone called ”Tortuga”. Please refer to the Company website at
www.silvercrestmines.com for further information.
N. Eric Fier, President and COO stated; “This delineation drill
program at Santa Elena was immensely successful. With this program, we
drilled the known portion of the deposit at approximately 35 metre
centres, announced revised reserves and resources, extended
mineralization beyond our current reserve boundary and identified three
new zones, El Cholugo, El Cholugo Dos and the newly discovered Tortuga.
The recently announced results of the revised underground reserve and
resource estimations have extended the current mine life to a minimum of
8 years . Our underground ramp has progressed beyond 1,500 metres in
development length. We have intercepted the Main Mineralized Zone
underground and extracted approximately 8,000 tonnes of ore from the 625
metre level. The conventional mill construction and underground
development currently underway are setting the stage for the successful
expansion of the mine with an anticipated significant increase in metals
production starting in 2014.”
Drill intercepts continue to expand the mineralization along the Main Mineralized Zone (MMZ) which remains open laterally and to depth. Intercepts are up to 100 metres beyond the boundary of current stope designs and reserves estimates. Most notable are the multiple high grade intercepts to the east and depth including;
The new Tortuga Zone is a northwest trending vein, breccia and stockwork zone outcropping on the surface and in the pit (see attached Figure). This zone is similar in mineralogy to the Main Mineralized Zone which is currently being successfully mined. This discovery has been drilled within an estimated area of 200 metres long by 300 metres high with an average thickness of approximately 3 metres. Numerous mineralized veins parallel or sub-parallel to the discovery were also intersected in drilling and are under review as potential additional targets. Tortuga is exposed in the north wall of the pit making this discovery easily accessible from the open pit and planned underground development of the adjacent MMZ. Further work is planned at Tortuga for resources estimation and subsequent potential conversion to reserves.
Mineralized intervals reported range from 0.5 metres to 16.0 metres further supporting the proposed underground bulk mining approach at Santa Elena. All mineralized drill intercepts reported are near true thicknesses. The most significant assay results in this series of drill holes are shown in the following tables (all numbers are rounded);
TORTUGA (NEW DISCOVERY)
MAIN MINERALIZED ZONE (MMZ)
EL CHOLUGO
EL CHOLUGO DOS
All sample analyses were completed by ALS Chemex in Hermosillo,
Mexico and North Vancouver, BC or the Santa Elena internal lab with
checks at ALS Chemex.
Of the 47 holes being reported above only three holes, SE-12-100, 101 and 183, intercepted no significant assay results. Holes SE-12-97, 98 and 99 were previously announced only as general mineralized intercepts with results stated above. Holes SE-12-100 and 101 were not previous announced with their locations off trend and north of the deposit.
Approximately 58,493 metres of drilling were completed in the delineation program to convert underground resources to reserves, expand total resources and test further potential outside the results of the Pre-Feasibiity Study. One drill is currently on site completing an underground program (planned 1,500 metres) for detailed design of first production stopes anticipated to be mined in late 2014.
The Qualified Person under National Instrument (NI 43-101) Standards of Disclosure for Mineral Projects for this News Release is N. Eric Fier, CPG, P.Eng, President and Chief Operating Officer for SilverCrest Mines Inc., who has reviewed and approved its contents.
SilverCrest Mines Inc. (TSX VENTURE:SVL)(NYSE MKT:SVLC) is a Canadian precious metals producer headquartered in Vancouver, BC. SilverCrest's flagship property is the 100%-owned Santa Elena Mine, located 150 km northeast of Hermosillo, near Banamichi in the State of Sonora, México. The mine is a high-grade, epithermal silver and gold producer, with an estimated life of mine cash cost of US$8 per ounce of silver equivalent (55:1 Ag: Au). SilverCrest anticipates that the 2,500 tonnes per day open pit heap leach facility at the Santa Elena mine should recover approximately 625,000 ounces of silver and 33,000 ounces of gold in 2013. Major expansion and construction of a 3000 tonnes per day conventional mill facility is underway to significantly increase metals production at the Santa Elena Mine (open pit and underground) by 2014. Exploration programs continue to make new discoveries at Santa Elena and also have rapidly advanced the definition of a large polymetallic deposit at the La Joya property in Durango State with stated resources nearing 200 million ounces of Ag equivalent.
FORWARD-LOOKING STATEMENTS
This news release contains "forward-looking statements" within the meaning of Canadian securities legislation and the United States Securities Litigation Reform Act of 1995. Such forward-looking statements concern the Company's anticipated results and developments in the Company's operations in future periods, planned exploration and development of its properties, plans related to its business and other matters that may occur in the future. These statements relate to analyses and other information that are based on expectations of future performance, including silver and gold production and planned work programs. Statements concerning reserves and mineral resource estimates may also constitute forward-looking statements to the extent that they involve estimates of the mineralization that will be encountered if the property is developed and, in the case of mineral reserves, such statements reflect the conclusion based on certain assumptions that the mineral deposit can be economically exploited.
Forward-looking statements are subject to a variety of known and unknown risks, uncertainties and other factors which could cause actual events or results to differ from those expressed or implied by the forward-looking statements, including, without limitation: risks related to precious and base metal price fluctuations; risks related to fluctuations in the currency markets (particularly the Mexican peso, Canadian dollar and United States dollar); risks related to the inherently dangerous activity of mining, including conditions or events beyond our control, and operating or technical difficulties in mineral exploration, development and mining activities; uncertainty in the Company's ability to raise financing and fund the exploration and development of its mineral properties; uncertainty as to actual capital costs, operating costs, production and economic returns, and uncertainty that development activities will result in profitable mining operations; risks related to reserves and mineral resource figures being estimates based on interpretations and assumptions which may result in less mineral production under actual conditions than is currently estimated and to diminishing quantities or grades of mineral reserves as properties are mined; risks related to governmental regulations and obtaining necessary licenses and permits; risks related to the business being subject to environmental laws and regulations which may increase costs of doing business and restrict our operations; risks related to mineral properties being subject to prior unregistered agreements, transfers, or claims and other defects in title; risks relating to inadequate insurance or inability to obtain insurance; risks related to potential litigation; risks related to the global economy; risks related to the Company's status as a foreign private issuer in the United States; risks related to all of the Company's properties being located in Mexico and El Salvador, including political, economic, social and regulatory instability; and risks related to officers and directors becoming associated with other natural resource companies which may give rise to conflicts of interests. Should one or more of these risks and uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described in the forward-looking statements. The Company's forward-looking statements are based on beliefs, expectations and opinions of management on the date the statements are made. For the reasons set forth above, investors should not place undue reliance on forward-looking statements.
The information provided in this news release is not intended to be a comprehensive review of all matters and developments concerning the Company. It should be read in conjunction with all other disclosure documents of the Company. The information contained herein is not a substitute for detailed investigation or analysis. No securities commission or regulatory authority has reviewed the accuracy or adequacy of the information presented.
N. Eric Fier
N. Eric Fier, President and COO
SILVERCREST MINES INC.
Contact:
SilverCrest Mines Inc.
Fred Cooper
(604) 694-1730 ext. 108
Toll Free: 1-866-691-1730
(604) 694-1761
info@silvercrestmines.com
www.silvercrestmines.com
Neither TSX Venture Exchange nor its Regulation Services Provider (as defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Published at Investorideas.com Newswire
Disclaimer / Disclosure : The Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising. Disclosure: SilverCrest Mines has compensated Investorideas.com for the distribution and publishing of this news release (annual news publication 9700) http://www.investorideas.com/About/Disclaimer.asp
BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894
Drill intercepts continue to expand the mineralization along the Main Mineralized Zone (MMZ) which remains open laterally and to depth. Intercepts are up to 100 metres beyond the boundary of current stope designs and reserves estimates. Most notable are the multiple high grade intercepts to the east and depth including;
- SE-13-144; 9.2 metres grading 4.83 gpt Au and 171.4 gpt Ag including 0.8 metres grading 30.20 gpt Au and 638.0 gpt Ag
- SE-13-152; 15.0 metres grading 4.03 gpt Au and 243.2 gpt Ag including 2.0 metres grading 17.5 gpt Au and 664.0 gpt Ag
- SE-13-160; 13.3 metres grading 3.52 gpt Au and 136.2 gpt Ag including 4.1 metres grading 6.46 gpt Au and 133.6 gpt Ag
- SE-13-166; 11.7 metres grading 3.97 gpt Au and 189.5 gpt Ag including 5.0 metres grading 8.10 gpt Au and 334.4 gpt Ag
- SE-13-175; 8.8 metres grading 1.91 gpt Au and 70.6 gpt Ag including 2.0 metres grading 6.70 gpt Au and 226.1 gpt Ag
The new Tortuga Zone is a northwest trending vein, breccia and stockwork zone outcropping on the surface and in the pit (see attached Figure). This zone is similar in mineralogy to the Main Mineralized Zone which is currently being successfully mined. This discovery has been drilled within an estimated area of 200 metres long by 300 metres high with an average thickness of approximately 3 metres. Numerous mineralized veins parallel or sub-parallel to the discovery were also intersected in drilling and are under review as potential additional targets. Tortuga is exposed in the north wall of the pit making this discovery easily accessible from the open pit and planned underground development of the adjacent MMZ. Further work is planned at Tortuga for resources estimation and subsequent potential conversion to reserves.
Mineralized intervals reported range from 0.5 metres to 16.0 metres further supporting the proposed underground bulk mining approach at Santa Elena. All mineralized drill intercepts reported are near true thicknesses. The most significant assay results in this series of drill holes are shown in the following tables (all numbers are rounded);
TORTUGA (NEW DISCOVERY)
MAIN MINERALIZED ZONE (MMZ)
EL CHOLUGO
EL CHOLUGO DOS
All sample analyses were completed by ALS Chemex in Hermosillo,
Mexico and North Vancouver, BC or the Santa Elena internal lab with
checks at ALS Chemex. Of the 47 holes being reported above only three holes, SE-12-100, 101 and 183, intercepted no significant assay results. Holes SE-12-97, 98 and 99 were previously announced only as general mineralized intercepts with results stated above. Holes SE-12-100 and 101 were not previous announced with their locations off trend and north of the deposit.
Approximately 58,493 metres of drilling were completed in the delineation program to convert underground resources to reserves, expand total resources and test further potential outside the results of the Pre-Feasibiity Study. One drill is currently on site completing an underground program (planned 1,500 metres) for detailed design of first production stopes anticipated to be mined in late 2014.
The Qualified Person under National Instrument (NI 43-101) Standards of Disclosure for Mineral Projects for this News Release is N. Eric Fier, CPG, P.Eng, President and Chief Operating Officer for SilverCrest Mines Inc., who has reviewed and approved its contents.
SilverCrest Mines Inc. (TSX VENTURE:SVL)(NYSE MKT:SVLC) is a Canadian precious metals producer headquartered in Vancouver, BC. SilverCrest's flagship property is the 100%-owned Santa Elena Mine, located 150 km northeast of Hermosillo, near Banamichi in the State of Sonora, México. The mine is a high-grade, epithermal silver and gold producer, with an estimated life of mine cash cost of US$8 per ounce of silver equivalent (55:1 Ag: Au). SilverCrest anticipates that the 2,500 tonnes per day open pit heap leach facility at the Santa Elena mine should recover approximately 625,000 ounces of silver and 33,000 ounces of gold in 2013. Major expansion and construction of a 3000 tonnes per day conventional mill facility is underway to significantly increase metals production at the Santa Elena Mine (open pit and underground) by 2014. Exploration programs continue to make new discoveries at Santa Elena and also have rapidly advanced the definition of a large polymetallic deposit at the La Joya property in Durango State with stated resources nearing 200 million ounces of Ag equivalent.
FORWARD-LOOKING STATEMENTS
This news release contains "forward-looking statements" within the meaning of Canadian securities legislation and the United States Securities Litigation Reform Act of 1995. Such forward-looking statements concern the Company's anticipated results and developments in the Company's operations in future periods, planned exploration and development of its properties, plans related to its business and other matters that may occur in the future. These statements relate to analyses and other information that are based on expectations of future performance, including silver and gold production and planned work programs. Statements concerning reserves and mineral resource estimates may also constitute forward-looking statements to the extent that they involve estimates of the mineralization that will be encountered if the property is developed and, in the case of mineral reserves, such statements reflect the conclusion based on certain assumptions that the mineral deposit can be economically exploited.
Forward-looking statements are subject to a variety of known and unknown risks, uncertainties and other factors which could cause actual events or results to differ from those expressed or implied by the forward-looking statements, including, without limitation: risks related to precious and base metal price fluctuations; risks related to fluctuations in the currency markets (particularly the Mexican peso, Canadian dollar and United States dollar); risks related to the inherently dangerous activity of mining, including conditions or events beyond our control, and operating or technical difficulties in mineral exploration, development and mining activities; uncertainty in the Company's ability to raise financing and fund the exploration and development of its mineral properties; uncertainty as to actual capital costs, operating costs, production and economic returns, and uncertainty that development activities will result in profitable mining operations; risks related to reserves and mineral resource figures being estimates based on interpretations and assumptions which may result in less mineral production under actual conditions than is currently estimated and to diminishing quantities or grades of mineral reserves as properties are mined; risks related to governmental regulations and obtaining necessary licenses and permits; risks related to the business being subject to environmental laws and regulations which may increase costs of doing business and restrict our operations; risks related to mineral properties being subject to prior unregistered agreements, transfers, or claims and other defects in title; risks relating to inadequate insurance or inability to obtain insurance; risks related to potential litigation; risks related to the global economy; risks related to the Company's status as a foreign private issuer in the United States; risks related to all of the Company's properties being located in Mexico and El Salvador, including political, economic, social and regulatory instability; and risks related to officers and directors becoming associated with other natural resource companies which may give rise to conflicts of interests. Should one or more of these risks and uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described in the forward-looking statements. The Company's forward-looking statements are based on beliefs, expectations and opinions of management on the date the statements are made. For the reasons set forth above, investors should not place undue reliance on forward-looking statements.
The information provided in this news release is not intended to be a comprehensive review of all matters and developments concerning the Company. It should be read in conjunction with all other disclosure documents of the Company. The information contained herein is not a substitute for detailed investigation or analysis. No securities commission or regulatory authority has reviewed the accuracy or adequacy of the information presented.
N. Eric Fier
N. Eric Fier, President and COO
SILVERCREST MINES INC.
Contact:
SilverCrest Mines Inc.
Fred Cooper
(604) 694-1730 ext. 108
Toll Free: 1-866-691-1730
(604) 694-1761
info@silvercrestmines.com
www.silvercrestmines.com
Neither TSX Venture Exchange nor its Regulation Services Provider (as defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Published at Investorideas.com Newswire
Disclaimer / Disclosure : The Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising. Disclosure: SilverCrest Mines has compensated Investorideas.com for the distribution and publishing of this news release (annual news publication 9700) http://www.investorideas.com/About/Disclaimer.asp
BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894
Medical Technology Breaking News: Aethlon Medical (OTCQB: AEMD) to Present at Exosomes and Circulating Biomarkers 2013 Summit
SAN DIEGO - September 5, 2013 (Investorideas.com newswire) Aethlon Medical, Inc. (OTCBB:AEMD),
announced today that Company Chairman and CEO, Jim Joyce has accepted
an invitation to present at the Exosomes and Circulating Biomarkers 2013
Summit on September 12th. Mr. Joyce's presentation is entitled;
"Extracorporeal Elimination of Circulating Exosomes as a Therapeutic
Adjunct to Address Infectious Disease and Cancer." The presentation will
highlight the clinical advancement of the Aethlon Hemopurifier® in
treating hepatitis c virus (HCV) and discuss the opportunity to expand
therapeutic indications to include cancer based on targeting the
elimination of circulating tumor-secreted exosomes. The conference will
be held at the Town and Country Resort Hotel in San Diego, California.
Aethlon is currently preparing to launch the first U.S. studies of
Hemopurifier® therapy based on the recent approval of an Investigational
Device Exemption (IDE) by the United States Food and Drug
Administration (FDA). Under the IDE, Aethlon will enroll ten end stage
renal disease (ESRD) patients infected with HCV as part of a feasibility
study to demonstrate Hemopurifier safety. Successful completion of the
feasibility study will set the stage for Aethlon to conduct pivotal
studies required for market clearance to treat HCV and other disease
conditions.
The conference abstract of the presentation follows:
Extracorporeal Elimination of Circulating Exosomes as a Therapeutic Adjunct to Address Infectious Disease and Cancer on 9/12/13 at 3:45pm pacific.
The Aethlon Hemopurifier® is a first-in-class device that targets the rapid elimination of infectious disease and cancer glycopathogens from circulation. In cancer, the Hemopurifier has been demonstrated to capture exosomes underlying lymphoma, melanoma, ovarian, and breast cancer. These microvesicular particles trigger apoptosis of immune cells and have been reported to facilitate tumor growth, metastasis, and the development of drug resistance.
In design, the Hemopurifier consists of the affinity lectin Galanthus nivalis agglutinin (GNA) immobilized in the outer-capillary space of plasma membrane technologies. The resulting mechanism provides selective target elimination as GNA binds high mannose signatures abundant on the surface of exosomes and viral glycoproteins. Studies of hepatitis c (HCV) infected patients receiving a three-treatment Hemopurifier protocol combined with interferon-based standard of care resulted in undetectable HCV in as little as seven days in hard-to-treat genotype-1 patients. The studies also documented the ability of the Hemopurifier to capture as many as 300 billion HCV copies during a single six- hour treatment. The FDA recently approved an IDE that allows for the initiation of US feasibility studies.
About Aethlon Medical
Aethlon Medical creates innovative medical devices that address unmet medical needs in cancer, infectious disease, and other life-threatening conditions. Our Aethlon ADAPT™ System is a revenue-stage technology platform that provides the basis for a new class of devices the rapid, yet selective removal of disease promoting particles from the entire circulatory system. At present, The Aethlon ADAPT™ product pipeline includes the Aethlon Hemopurifier® to address infectious disease and cancer, and a medical device being developed under a 5-year contract with Defense Advanced Research Projects Agency (DARPA) to reduce the incidence of sepsis in combat-injured soldiers. For more information, please visit www.aethlonmedical.com.
Certain statements herein may be forward-looking and involve risks and uncertainties. Such forward-looking statements involve assumptions, known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Aethlon Medical, Inc. to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such potential risks and uncertainties include, without limitation, that the company can successfully protect its intellectual property, that removal of exosomes from the human body will impact or lead to successful treatment of cancer, or that exosomes are the cause of tumor growth and progression, that the FDA will not approve the initiation of the Company's clinical programs or provide market clearance of the company's products, future human studies whether revenue or non-revenue generating of the Aethlon ADAPT™ system or the Aethlon Hemopurifier® as an adjunct therapy to improve patient responsiveness to established cancer or hepatitis C therapies or as a standalone cancer or hepatitis C therapy, the Company's ability to raise capital when needed, the Company's ability to complete the development of its planned products, the Company's ability to manufacture its products either internally or through outside companies and provide its services, the impact of government regulations, patent protection on the Company's proprietary technology, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors. In such instances, actual results could differ materially as a result of a variety of factors, including the risks associated with the effect of changing economic conditions and other risk factors detailed in the Company's Securities and Exchange Commission filings. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.
Contacts:
James A. Joyce
Chairman and CEO
858.459.7800 x301
jj@aethlonmedical.com
Jim Frakes
Chief Financial Officer
858.459.7800 x300
jfrakes@aethlonmedical.com
Marc Robins
877.276.2467
mr@aethlonmedical.com
Published at Investorideas.com newswire
Sign up for the free investor news and stock alerts
http://www.investorideas.com/Resources/Newsletter.asp
Disclaimer / Disclosure : The Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. Disclosure: Investorideas has been compensated by AEMD for news distribution and content publishing: three thousand per month effective June 2013
http://www.investorideas.com/About/Disclaimer.asp
This site is currently compensated by featured companies, news submissions and online advertising.
BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar
The conference abstract of the presentation follows:
Extracorporeal Elimination of Circulating Exosomes as a Therapeutic Adjunct to Address Infectious Disease and Cancer on 9/12/13 at 3:45pm pacific.
The Aethlon Hemopurifier® is a first-in-class device that targets the rapid elimination of infectious disease and cancer glycopathogens from circulation. In cancer, the Hemopurifier has been demonstrated to capture exosomes underlying lymphoma, melanoma, ovarian, and breast cancer. These microvesicular particles trigger apoptosis of immune cells and have been reported to facilitate tumor growth, metastasis, and the development of drug resistance.
In design, the Hemopurifier consists of the affinity lectin Galanthus nivalis agglutinin (GNA) immobilized in the outer-capillary space of plasma membrane technologies. The resulting mechanism provides selective target elimination as GNA binds high mannose signatures abundant on the surface of exosomes and viral glycoproteins. Studies of hepatitis c (HCV) infected patients receiving a three-treatment Hemopurifier protocol combined with interferon-based standard of care resulted in undetectable HCV in as little as seven days in hard-to-treat genotype-1 patients. The studies also documented the ability of the Hemopurifier to capture as many as 300 billion HCV copies during a single six- hour treatment. The FDA recently approved an IDE that allows for the initiation of US feasibility studies.
About Aethlon Medical
Aethlon Medical creates innovative medical devices that address unmet medical needs in cancer, infectious disease, and other life-threatening conditions. Our Aethlon ADAPT™ System is a revenue-stage technology platform that provides the basis for a new class of devices the rapid, yet selective removal of disease promoting particles from the entire circulatory system. At present, The Aethlon ADAPT™ product pipeline includes the Aethlon Hemopurifier® to address infectious disease and cancer, and a medical device being developed under a 5-year contract with Defense Advanced Research Projects Agency (DARPA) to reduce the incidence of sepsis in combat-injured soldiers. For more information, please visit www.aethlonmedical.com.
Certain statements herein may be forward-looking and involve risks and uncertainties. Such forward-looking statements involve assumptions, known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Aethlon Medical, Inc. to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such potential risks and uncertainties include, without limitation, that the company can successfully protect its intellectual property, that removal of exosomes from the human body will impact or lead to successful treatment of cancer, or that exosomes are the cause of tumor growth and progression, that the FDA will not approve the initiation of the Company's clinical programs or provide market clearance of the company's products, future human studies whether revenue or non-revenue generating of the Aethlon ADAPT™ system or the Aethlon Hemopurifier® as an adjunct therapy to improve patient responsiveness to established cancer or hepatitis C therapies or as a standalone cancer or hepatitis C therapy, the Company's ability to raise capital when needed, the Company's ability to complete the development of its planned products, the Company's ability to manufacture its products either internally or through outside companies and provide its services, the impact of government regulations, patent protection on the Company's proprietary technology, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors. In such instances, actual results could differ materially as a result of a variety of factors, including the risks associated with the effect of changing economic conditions and other risk factors detailed in the Company's Securities and Exchange Commission filings. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.
Contacts:
James A. Joyce
Chairman and CEO
858.459.7800 x301
jj@aethlonmedical.com
Jim Frakes
Chief Financial Officer
858.459.7800 x300
jfrakes@aethlonmedical.com
Marc Robins
877.276.2467
mr@aethlonmedical.com
Published at Investorideas.com newswire
Sign up for the free investor news and stock alerts
http://www.investorideas.com/Resources/Newsletter.asp
Disclaimer / Disclosure : The Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. Disclosure: Investorideas has been compensated by AEMD for news distribution and content publishing: three thousand per month effective June 2013
http://www.investorideas.com/About/Disclaimer.asp
This site is currently compensated by featured companies, news submissions and online advertising.
BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar
Subscribe to:
Posts (Atom)